Disease Information
General Information of the Disease (ID: DIS00062)
Name |
Osteosarcoma
|
---|---|
ICD |
ICD-11: 2B51
|
Resistance Map |
Type(s) of Resistant Mechanism of This Disease
DISM: Drug Inactivation by Structure Modification
EADR: Epigenetic Alteration of DNA, RNA or Protein
IDUE: Irregularity in Drug Uptake and Drug Efflux
RTDM: Regulation by the Disease Microenvironment
UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Drug
Approved Drug(s)
17 drug(s) in total
Bortezomib
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-mir-101 | [1] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Bortezomib | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
Flow cytometry assay | |||
Mechanism Description | miR-101 functions as an endogenous proteasome inhibitor by targeting POMP. Targeting POMP is essential for cell growth suppression by miR-101. High miR-101 levels have good outcomes for ERalpha-positive breast cancer patients. Targeting POMP inhibits tumor progression and overcomes resistance to bortezomib. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Proteasome maturation protein (POMP) | [1] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Bortezomib | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
Flow cytometry assay | |||
Mechanism Description | miR-101 functions as an endogenous proteasome inhibitor by targeting POMP. Targeting POMP is essential for cell growth suppression by miR-101. High miR-101 levels have good outcomes for ERalpha-positive breast cancer patients. Targeting POMP inhibits tumor progression and overcomes resistance to bortezomib. |
Carboplatin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-miR-34a-5p | [2] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Carboplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Annexin V-FITC/propidium iodide (PI) staining assay | |||
Mechanism Description | The miR34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene. | |||
Key Molecule: hsa-miR-199a-3p | [3] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Carboplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell viability | Activation | hsa05200 | |
NF-kappaB signaling pathway | Inhibition | hsa04064 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | The Ak4 gene is one of the targets of miR-199a-3p and negatively correlates with the effect of miR-199a-3p on OS drug-resistance. | |||
Key Molecule: hsa-miR-34a-5p | [4] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Carboplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Activation | hsa05200 | |
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
MEF2 signaling pathway | Regulation | hsa04013 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 | |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
MG63.2 cells | Bone | Homo sapiens (Human) | CVCL_R705 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | The down-regulation of CD117 mediated by miR-34a-5p might be one of the reasons for OS drug resistance. CD117 may also regulate other processes, including cell adhesion, differentiation and migration, which are significant for cancer development and treatment. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Type-1 angiotensin II receptor (AGTR1) | [2] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Carboplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay; Annexin V-FITC/propidium iodide (PI) staining assay | |||
Mechanism Description | The miR34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene. | |||
Key Molecule: Adenylate kinase 4 (AK4) | [3] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Carboplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell viability | Activation | hsa05200 | |
NF-kappaB signaling pathway | Inhibition | hsa04064 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis; RIP assay; Luciferase reporter assay | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | The Ak4 gene is one of the targets of miR-199a-3p and negatively correlates with the effect of miR-199a-3p on OS drug-resistance. | |||
Key Molecule: Mast/stem cell growth factor receptor Kit (KIT) | [4] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Carboplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Activation | hsa05200 | |
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
MEF2 signaling pathway | Regulation | hsa04013 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 | |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
MG63.2 cells | Bone | Homo sapiens (Human) | CVCL_R705 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | The down-regulation of CD117 mediated by miR-34a-5p might be one of the reasons for OS drug resistance. CD117 may also regulate other processes, including cell adhesion, differentiation and migration, which are significant for cancer development and treatment. |
Cisplatin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: OIP5 antisense RNA 1 (OIP5-AS1) | [5] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell proliferation | Activation | hsa05200 | ||
PI3K/AKT/mTOR signaling pathway | Activation | hsa04151 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qPCR | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | OIP5-AS1 regulates cisplatin resistance by activating the PI3k/AkT/mTOR signaling pathway. | |||
Key Molecule: hsa-miR-340-5p | [5] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell proliferation | Activation | hsa05200 | ||
PI3K/AKT/mTOR signaling pathway | Activation | hsa04151 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
RT-qPCR | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | OIP5-AS1 regulates cisplatin resistance by activating the PI3k/AkT/mTOR signaling pathway. | |||
Key Molecule: hsa-miR-34a-5p | [2], [6] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | ATF2/ATF3/ATF4 signaling pathway | Inhibition | hsa04915 | |
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Annexin V-FITC/propidium iodide (PI) staining assay | |||
Mechanism Description | The miR34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene. And miR34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene. | |||
Key Molecule: Delta-like protein 1 (DLL1) | [6] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | ATF2/ATF3/ATF4 signaling pathway | Inhibition | hsa04915 | |
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
MG63.2 cells | Bone | Homo sapiens (Human) | CVCL_R705 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
IC50 assay; Flow cytometric analysis | |||
Mechanism Description | miR34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene. The activity of the ATF2/ATF3/ATF4 pathway was reduced in the miR34a-5p mimic-transfected G-292 cells but increased in the miR34a-5p antagomiRtransfected SJSA-1 cells, hence the ATF2/ATF3/ATF4 pathway was validated to be involved in the OS chemoresistance mediated by miR34a-5p. | |||
Key Molecule: hsa-miR-199a-3p | [3] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell viability | Activation | hsa05200 | |
NF-kappaB signaling pathway | Inhibition | hsa04064 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | The Ak4 gene is one of the targets of miR-199a-3p and negatively correlates with the effect of miR-199a-3p on OS drug-resistance. | |||
Key Molecule: Nuclear paraspeckle assembly transcript 1 (NEAT1) | [7] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | BCL2/cyclin D1 signaling pathway | Inhibition | hsa04210 | |
Cell apoptosis | Inhibition | hsa04210 | ||
Cell viability | Activation | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
143B cells | Bone | Homo sapiens (Human) | CVCL_2270 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qPCR | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | The miR-34c inhibitor restored the BCL-2 and cyclin D1 levels in MG63 and HOS cell line, which implicated that NEAT1 inhibited the tumor suppressor miR-34c and up-regulated cell survival signals for the development of OS. | |||
Key Molecule: hsa-mir-377 | [8] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell viability | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
MG63/CDDP cells | Bone | Homo sapiens (Human) | CVCL_0426 | |
SAOS-2/CDDP cells | Bone | Homo sapiens (Human) | CVCL_0548 | |
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | XIAP overexpression greatly cancelled the apoptosis promoting the effect of miR377 in Saos-2/CDDP cell. | |||
Key Molecule: hsa_circ_PVT1 | [9] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell colony | Activation | hsa05200 | |
Cell viability | Activation | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
KHOS cells | Bone | Homo sapiens (Human) | CVCL_2546 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay; Colony formation assay | |||
Mechanism Description | CircPVT1 knockdown reduces the expression of classical multidrug resistance related gene-ABCB1 in OS cells. | |||
Key Molecule: hsa-mir-340 | [10] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell viability | Activation | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
Experiment for Molecule Alteration |
PCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | Overexpression of ZEB1 reversed the miR-340-induced alleviation of chemoresistance in drug-resistant OS cells. | |||
Key Molecule: hsa-miR-34a-5p | [4] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Activation | hsa05200 | |
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
MEF2 signaling pathway | Regulation | hsa04013 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 | |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
MG63.2 cells | Bone | Homo sapiens (Human) | CVCL_R705 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | The down-regulation of CD117 mediated by miR-34a-5p might be one of the reasons for OS drug resistance. CD117 may also regulate other processes, including cell adhesion, differentiation and migration, which are significant for cancer development and treatment. | |||
Key Molecule: hsa-miR-146b-5p | [11] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell invasion | Activation | hsa05200 | ||
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
Wnt/Beta-catenin signaling pathway | Regulation | hsa04310 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
hFOB1.19 cells | Fetal bone | Homo sapiens (Human) | CVCL_3708 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | miR-146b-5p was highly expressed in human osteosarcoma tissues and an elevated expression of miR-146b-5p was observed in human osteosarcoma tissues after chemotherapy. Furthermore, it was shown that miR-146b-5p overexpression promoted migration and invasiveness. miR-146b-5p overexpression also increased resistance to chemotherapy. Moreover, knockdown of miR-146b-5p substantially inhibited migration and invasion of osteosarcoma cells as well as rendered them significantly more sensitive to chemotherapy. Results of western blot assay indicated that miR-146b-5p increased MMP-16 protein expression and showed a decrease of ZNRF3 protein. Whereas, IWR-1-endo, an inhibitor of Wnt/beta-catenin, suppressed the decrease in apoptosis of osteosarcoma cells caused by miR-146b-5p overexpression. These results indicated that miR-146b-5p promoted proliferation, migration and invasiveness. | |||
Key Molecule: hsa-mir-33a | [12] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
TUNEL assay | |||
Mechanism Description | miR-33a is up-regulated in chemoresistant OS and that the miR-33a level is negatively correlated with the TWIST protein level in OS. miR-33a promotes OS cell resistance to cisplatin by down-regulating TWIST. | |||
Key Molecule: hsa-mir-221 | [13] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
PI3K/AKT signaling pathway | Regulation | hsa04151 | ||
In Vitro Model | SOSP-9607 cells | Bones | Homo sapiens (Human) | CVCL_4V80 |
SOSP-9901 cells | Bones | Homo sapiens (Human) | N.A. | |
Experiment for Molecule Alteration |
qRT-PCR; RT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR-221 induce cell survival and cisplatin resistance in human osteosarcoma at least partly through targeting the PI3k/PTEN/Akt pathway. | |||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: Multidrug resistance protein 1 (ABCB1) | [9] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell colony | Activation | hsa05200 | |
Cell viability | Activation | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
KHOS cells | Bone | Homo sapiens (Human) | CVCL_2546 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay; Colony formation assay | |||
Mechanism Description | CircPVT1 knockdown reduces the expression of classical multidrug resistance related gene-ABCB1 in OS cells. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Interleukin-24 (IL24) | [14] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | ZBTB7A/LINC00473/IL24 signaling pathway | Regulation | hsa04630 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
RT-PCR; Dual-Luciferase reporter assay | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | LINC00473 promoted the activity of IL24 promoter and elevated IL24 expression. LINC00473 interacts with the transcript factor C/EBPbeta, facilitating its binding to the promoter of IL24, leading to decrease chemoresistance. The ZBTB7A-LINC00473-IL24 signaling axis plays an important role in regulating osteosarcoma chemoresistance. | |||
Key Molecule: Zinc finger and BTB domain-containing protein 7A (ZBTB7A) | [14] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | ZBTB7A/LINC00473/IL24 signaling pathway | Regulation | hsa04630 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
qPCR | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | Elevated ZBTB7A inhibits cisplatin-induced apoptosis by repressing LINC00473 expression. The ZBTB7A-LINC00473-IL24 signaling axis plays an important role in regulating osteosarcoma chemoresistance. | |||
Key Molecule: Type-1 angiotensin II receptor (AGTR1) | [2] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay; Annexin V-FITC/propidium iodide (PI) staining assay | |||
Mechanism Description | The miR34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene. | |||
Key Molecule: Interferon-induced protein with tetratricopeptide repeats 2 (IFIT2) | [15] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell colony | Inhibition | hsa05200 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
Ckk-8 assay; Colony formation assay; Annexin V-FITC staining assay | |||
Mechanism Description | Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR645-IFIT2 axis. LINC00161 upregulated IFIT2 expression via miR645. | |||
Key Molecule: Adenylate kinase 4 (AK4) | [3] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell viability | Activation | hsa05200 | |
NF-kappaB signaling pathway | Inhibition | hsa04064 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis; RIP assay; Luciferase reporter assay | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | The Ak4 gene is one of the targets of miR-199a-3p and negatively correlates with the effect of miR-199a-3p on OS drug-resistance. | |||
Key Molecule: Apoptosis regulator Bcl-2 (BCL2) | [7] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | BCL2/cyclin D1 signaling pathway | Inhibition | hsa04210 | |
Cell apoptosis | Inhibition | hsa04210 | ||
Cell viability | Activation | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
143B cells | Bone | Homo sapiens (Human) | CVCL_2270 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | The miR-34c inhibitor restored the BCL-2 and cyclin D1 levels in MG63 and HOS cell line, which implicated that NEAT1 inhibited the tumor suppressor miR-34c and up-regulated cell survival signals for the development of OS. | |||
Key Molecule: G1/S-specific cyclin-D1 (CCND1) | [7] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | BCL2/cyclin D1 signaling pathway | Inhibition | hsa04210 | |
Cell apoptosis | Inhibition | hsa04210 | ||
Cell viability | Activation | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
143B cells | Bone | Homo sapiens (Human) | CVCL_2270 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | The miR-34c inhibitor restored the BCL-2 and cyclin D1 levels in MG63 and HOS cell line, which implicated that NEAT1 inhibited the tumor suppressor miR-34c and up-regulated cell survival signals for the development of OS. | |||
Key Molecule: E3 ubiquitin-protein ligase XIAP (XIAP) | [8] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell viability | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
MG63/CDDP cells | Bone | Homo sapiens (Human) | CVCL_0426 | |
SAOS-2/CDDP cells | Bone | Homo sapiens (Human) | CVCL_0548 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | XIAP overexpression greatly cancelled the apoptosis promoting the effect of miR377 in Saos-2/CDDP cell. | |||
Key Molecule: Zinc finger E-box-binding homeobox 1 (ZEB1) | [10] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell viability | Activation | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | Overexpression of ZEB1 reversed the miR-340-induced alleviation of chemoresistance in drug-resistant OS cells. | |||
Key Molecule: Mast/stem cell growth factor receptor Kit (KIT) | [4] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Activation | hsa05200 | |
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
MEF2 signaling pathway | Regulation | hsa04013 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 | |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
MG63.2 cells | Bone | Homo sapiens (Human) | CVCL_R705 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | The down-regulation of CD117 mediated by miR-34a-5p might be one of the reasons for OS drug resistance. CD117 may also regulate other processes, including cell adhesion, differentiation and migration, which are significant for cancer development and treatment. | |||
Key Molecule: E3 ubiquitin-protein ligase ZNRF3 (ZNRF3) | [11] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell invasion | Activation | hsa05200 | ||
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
Wnt/Beta-catenin signaling pathway | Regulation | hsa04310 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
hFOB1.19 cells | Fetal bone | Homo sapiens (Human) | CVCL_3708 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | miR-146b-5p was highly expressed in human osteosarcoma tissues and an elevated expression of miR-146b-5p was observed in human osteosarcoma tissues after chemotherapy. Furthermore, it was shown that miR-146b-5p overexpression promoted migration and invasiveness. miR-146b-5p overexpression also increased resistance to chemotherapy. Moreover, knockdown of miR-146b-5p substantially inhibited migration and invasion of osteosarcoma cells as well as rendered them significantly more sensitive to chemotherapy. Results of western blot assay indicated that miR-146b-5p increased MMP-16 protein expression and showed a decrease of ZNRF3 protein. Whereas, IWR-1-endo, an inhibitor of Wnt/beta-catenin, suppressed the decrease in apoptosis of osteosarcoma cells caused by miR-146b-5p overexpression. These results indicated that miR-146b-5p promoted proliferation, migration and invasiveness. | |||
Key Molecule: Twist-related protein 1 (TWST1) | [12] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
TUNEL assay | |||
Mechanism Description | miR-33a is up-regulated in chemoresistant OS and that the miR-33a level is negatively correlated with the TWIST protein level in OS. miR-33a promotes OS cell resistance to cisplatin by down-regulating TWIST. | |||
Key Molecule: Phosphatase and tensin homolog (PTEN) | [13] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Cisplatin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
PI3K/AKT signaling pathway | Regulation | hsa04151 | ||
In Vitro Model | SOSP-9607 cells | Bones | Homo sapiens (Human) | CVCL_4V80 |
SOSP-9901 cells | Bones | Homo sapiens (Human) | N.A. | |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR-221 induce cell survival and cisplatin resistance in human osteosarcoma at least partly through targeting the PI3k/PTEN/Akt pathway. |
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-mir-34 | [16] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Bim signaling pathway | Activation | hsa05206 | |
c-Myc signaling pathway | Activation | hsa05230 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
Experiment for Molecule Alteration |
RT-qPCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometric analysis | |||
Mechanism Description | miR34a increases cisplatin sensitivity of osteosarcoma cells in vitro through up-regulation of c-Myc and Bim signal. | |||
Key Molecule: hsa-mir-200c | [17] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell migration | Inhibition | hsa04670 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
RT-PCR; RT-qPCR | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometric analysis; Caspase-3 Activity Assay | |||
Mechanism Description | miR200c regulates tumor growth and chemosensitivity to cisplatin in osteosarcoma by targeting AkT2 and inhibiting the activity of cell proliferation and cell migration. | |||
Key Molecule: Long non-protein coding RNA (LINC00473) | [14] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | ZBTB7A/LINC00473/IL24 signaling pathway | Regulation | hsa04630 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
qPCR | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | LINC00473 promoted the activity of IL24 promoter and elevated IL24 expression. LINC00473 interacts with the transcript factor C/EBPbeta, facilitating its binding to the promoter of IL24, leading to decrease chemoresistance. The ZBTB7A-LINC00473-IL24 signaling axis plays an important role in regulating osteosarcoma chemoresistance. | |||
Key Molecule: hsa-mir-491 | [18] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
RT-PCR; RT-qPCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | Overexpression of miR491 inhibits chemoresistance and suppresses OS cell lung metastasis, whereas it enhances cisplatin (CDDP)-induced tumor growth inhibition and apoptosis, miR491 exerts its role by directly targeting alphaB-crystallin (CRYAB) in OS. | |||
Key Molecule: hsa-miR-340-5p | [19] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
MG63/CDDP cells | Bone | Homo sapiens (Human) | CVCL_0426 | |
SAOS-2/CDDP cells | Bone | Homo sapiens (Human) | CVCL_0548 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay; Annexin V-FITC apoptosis assay | |||
Mechanism Description | microRNA-340-5p modulates cisplatin resistance by targeting LPAATbeta in osteosarcoma. | |||
Key Molecule: hsa-mir-410 | [20] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | HEK293T cells | Kidney | Homo sapiens (Human) | CVCL_0063 |
MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HFob 1.19 | Bone | Homo sapiens (Human) | CVCL_3708 | |
Experiment for Molecule Alteration |
RT-qPCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | microRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma, miR410 directly decreased ATG16L1 expression by targeting its 3'-untranslated region. | |||
Key Molecule: hsa-miR-199a-5p | [21] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
Experiment for Molecule Alteration |
RT-qPCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR199a-5p directly targeted Beclin1 and negatively mediated Beclin1 expression at a post-transcriptional level, microRNA-199a-5p inhibits cisplatin-induced drug resistance via inhibition of autophagy in osteosarcoma cells. | |||
Key Molecule: hsa-miR-422a | [22] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Inhibition | hsa05200 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HFOB cells | Bone | Homo sapiens (Human) | CVCL_3708 | |
Experiment for Molecule Alteration |
qPCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometric analysis of apoptosis; Transwell assay | |||
Mechanism Description | Overexpression of miR422a inhibits cell proliferation and invasion, and enhances chemosensitivity by directly targeting TGFbeta2 in osteosarcoma cells. | |||
Key Molecule: hsa-mir-381 | [23] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | mTOR signaling pathway | Regulation | hsa04150 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay; Matrigel chamber invasion assay | |||
Mechanism Description | There is a strong negative correlation between the expression of miR381 and LRRC4, suppressing the expression of miR381 increases the sensitivity of OS cells to chemotherapeutic drugs through the LRRC4-mediated mTOR pathway. | |||
Key Molecule: Long non-protein coding RNA 161 (LINC00161) | [15] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
Ckk-8 assay; Colony formation assay; Annexin V-FITC staining assay | |||
Mechanism Description | Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR645-IFIT2 axis. LINC00161 acted as a miR645 sponge and inhibited its activity. | |||
Key Molecule: hsa-miR-645 | [15] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
Ckk-8 assay; Colony formation assay; Annexin V-FITC staining assay | |||
Mechanism Description | Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR645-IFIT2 axis. LINC00161 acted as a miR645 sponge and inhibited its activity. | |||
Key Molecule: CDKN2B antisense RNA 1 (CDKN2B-AS1) | [24] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell colony | Inhibition | hsa05200 | ||
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | HEK293T cells | Kidney | Homo sapiens (Human) | CVCL_0063 |
MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 | |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | ANRIL-silenced cells were more sensitive to cisplatin and the expression level of miR-125a-5p was elevated in ANRIL-silenced cells. | |||
Key Molecule: hsa-miR-125a-5p | [24] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell colony | Inhibition | hsa05200 | ||
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | HEK293T cells | Kidney | Homo sapiens (Human) | CVCL_0063 |
MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 | |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | ANRIL-silenced cells were more sensitive to cisplatin and the expression level of miR-125a-5p was elevated in ANRIL-silenced cells. | |||
Key Molecule: hsa-mir-92a | [25] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell viability | Inhibition | hsa05200 | ||
Notch1 signaling pathway | Regulation | hsa04330 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
HFOB cells | Bone | Homo sapiens (Human) | CVCL_3708 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay; Transwell assay | |||
Mechanism Description | miR-92a inhibited cell growth, migration, and enhanced cisplatin sensitivity of OS cell by downregulating Notch1. | |||
Key Molecule: hsa-mir-34c | [7] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | BCL2/cyclin D1 signaling pathway | Inhibition | hsa04210 | |
Cell apoptosis | Activation | hsa04210 | ||
Cell viability | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
143B cells | Bone | Homo sapiens (Human) | CVCL_2270 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | The miR-34c inhibitor restored the BCL-2 and cyclin D1 levels in MG63 and HOS cell line, which implicated that NEAT1 inhibited the tumor suppressor miR-34c and up-regulated cell survival signals for the development of OS. | |||
Key Molecule: hsa-mir-22 | [26] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell viability | Inhibition | hsa05200 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
Experiment for Molecule Alteration |
RT-qPCR | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | miR-22 overexpression sensitizes MG-63 cells to cisplatin treatment and reduces the expression of S100A11. | |||
Key Molecule: hsa-mir-223 | [27] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell viability | Inhibition | hsa05200 | ||
JNk signaling pathway | Activation | hsa04010 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
Sk-ES-1 cells | Bone | Homo sapiens (Human) | CVCL_0627 | |
Experiment for Molecule Alteration |
qPCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | miR-223 overexpression could sensitize OS cell lines to CDDP and Hsp70 protein levels were remarkably reduced by miR-223 overexpression whereas increased by miR-223 inhibition. | |||
Key Molecule: hsa-mir-21 | [28] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell proliferation | Activation | hsa05200 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
143B cells | Bone | Homo sapiens (Human) | CVCL_2270 | |
HLNG cells | Bone marrow | Homo sapiens (Human) | N.A. | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Northern blot analysis | |||
Experiment for Drug Resistance |
Scratch assay | |||
Mechanism Description | miR-21 regulatory network plays a role in tumorigenesis of osteosarcoma. Its expression facilitates cell proliferation and decreases cellular sensitivity towards cisplatin. Both effects can be rescued by Spry2, a target protein downregulated by increased miR-21 levels. | |||
Key Molecule: hsa-mir-138 | [29] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Inhibition | hsa05200 | |
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
miR138/EZH2 signaling pathway | Regulation | hsa05206 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
In Vivo Model | BALB/c nu/nu nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | miR-138 acts as a tumor suppressor in osteosarcoma, inhibiting cell proliferation, migration, and invasion by downregulating EZH2 expression. Mir-138 overexpression also enhances osteosarcoma cell chemosensitivity to cisplatin by targeting EZH2. | |||
Key Molecule: hsa-mir-125b | [30] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Inhibition | hsa05200 | |
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
p53/p38/MAPK signaling pathway | Regulation | hsa04010 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | Overexpression of miR-125b inhibited proliferation, migration, and invasion of OS cells and reduced the chemotherapy resistance of OS cells to cisplatin by targeting Bcl-2. | |||
Key Molecule: hsa-mir-382 | [31] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | Decreased miR-382 was associated with poor survival in OS patients. Overexpression of miR-382 inhibited cell growth and chemoresistance by targeting kLF12 and HIPk3, respectively. In contrast, inhibition of miR-382 or overexpression of target genes stimulated OS cell growth and chemoresistance both in vitro and in vivo. | |||
Key Molecule: hsa-mir-29b | [32] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | 3AB-OS CSC cells | Bone marrow | Homo sapiens (Human) | CVCL_LM95 |
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
Trypan blue assay; Flow cytometry assay | |||
Mechanism Description | miR-29b-1 overexpression sensitized 3AB-OS cells to chemotherapeutic drug-induced apoptosis miR-29b-1 negatively regulated the expression of Bcl-2. | |||
Key Molecule: hsa-mir-103 | [33] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
Survival assay/crystal violet staining assay | |||
Mechanism Description | miR-103 and miR-107 reduced homology-directed repair and sensitized cells to various DNA damaging agents, including cisplatin and a PARP inhibitor. Mechanistic analyses revealed that both miR-103 and miR-107 directly target and regulate RAD51 and RAD51D, which is critical for miR-103/107-mediated chemosensitization. | |||
Key Molecule: hsa-miR-107 | [33] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
Survival assay/crystal violet staining assay | |||
Mechanism Description | miR-103 and miR-107 reduced homology-directed repair and sensitized cells to various DNA damaging agents, including cisplatin and a PARP inhibitor. Mechanistic analyses revealed that both miR-103 and miR-107 directly target and regulate RAD51 and RAD51D, which is critical for miR-103/107-mediated chemosensitization. | |||
Key Molecule: hsa-mir-96 | [34] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
Flow cytometry assay | |||
Mechanism Description | Overexpression of miR-96 in human cancer cells reduces the levels of RAD51 and REV1 and impacts the cellular response to agents that cause DNA damage. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: RAC-beta serine/threonine-protein kinase (AKT2) | [17] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell migration | Inhibition | hsa04670 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Luciferase reporter assay | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometric analysis; Caspase-3 Activity Assay | |||
Mechanism Description | miR200c regulates tumor growth and chemosensitivity to cisplatin in osteosarcoma by targeting AkT2 and inhibiting the activity of cell proliferation and cell migration. | |||
Key Molecule: Alpha-crystallin B chain (CRYAB) | [18] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR; Luciferase reporter assay; Western blot analysis; Western blot analysis; Immunohistochemistry assay | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | Overexpression of miR491 inhibits chemoresistance and suppresses OS cell lung metastasis, whereas it enhances cisplatin (CDDP)-induced tumor growth inhibition and apoptosis, miR491 exerts its role by directly targeting alphaB-crystallin (CRYAB) in OS. | |||
Key Molecule: Lysophosphatidic acid acyltransferase beta (AGPAT2) | [19] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
MG63/CDDP cells | Bone | Homo sapiens (Human) | CVCL_0426 | |
SAOS-2/CDDP cells | Bone | Homo sapiens (Human) | CVCL_0548 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay; Annexin V-FITC apoptosis assay | |||
Mechanism Description | microRNA-340-5p modulates cisplatin resistance by targeting LPAATbeta in osteosarcoma. | |||
Key Molecule: Autophagy-related protein 16-1 (ATG16L1) | [20] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | HEK293T cells | Kidney | Homo sapiens (Human) | CVCL_0063 |
MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HFob 1.19 | Bone | Homo sapiens (Human) | CVCL_3708 | |
Experiment for Molecule Alteration |
Luciferase reporter assay; Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | microRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma, miR410 directly decreased ATG16L1 expression by targeting its 3'-untranslated region. | |||
Key Molecule: Beclin-1 (BECN1) | [21] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR199a-5p directly targeted Beclin1 and negatively mediated Beclin1 expression at a post-transcriptional level, microRNA-199a-5p inhibits cisplatin-induced drug resistance via inhibition of autophagy in osteosarcoma cells. | |||
Key Molecule: Transforming growth factor beta-2 proprotein (TGFB2) | [22] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Inhibition | hsa05200 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HFOB cells | Bone | Homo sapiens (Human) | CVCL_3708 | |
Experiment for Molecule Alteration |
Western blot analysis; Dual luciferase activity assay | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometric analysis of apoptosis; Transwell assay | |||
Mechanism Description | Overexpression of miR422a inhibits cell proliferation and invasion, and enhances chemosensitivity by directly targeting TGFbeta2 in osteosarcoma cells. | |||
Key Molecule: Leucine-rich repeat-containing protein 4 (LRRC4) | [23] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | mTOR signaling pathway | Regulation | hsa04150 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay; Matrigel chamber invasion assay | |||
Mechanism Description | There is a strong negative correlation between the expression of miR381 and LRRC4, suppressing the expression of miR381 increases the sensitivity of OS cells to chemotherapeutic drugs through the LRRC4-mediated mTOR pathway. | |||
Key Molecule: Neurogenic locus notch homolog protein 1 (NOTCH1) | [25] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell viability | Inhibition | hsa05200 | ||
Notch1 signaling pathway | Regulation | hsa04330 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
HFOB cells | Bone | Homo sapiens (Human) | CVCL_3708 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay; Transwell assay | |||
Mechanism Description | miR-92a inhibited cell growth, migration, and enhanced cisplatin sensitivity of OS cell by downregulating Notch1. | |||
Key Molecule: Nuclear paraspeckle assembly transcript 1 (NEAT1) | [7] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | BCL2/cyclin D1 signaling pathway | Inhibition | hsa04210 | |
Cell apoptosis | Activation | hsa04210 | ||
Cell viability | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
143B cells | Bone | Homo sapiens (Human) | CVCL_2270 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | The miR-34c inhibitor restored the BCL-2 and cyclin D1 levels in MG63 and HOS cell line, which implicated that NEAT1 inhibited the tumor suppressor miR-34c and up-regulated cell survival signals for the development of OS. | |||
Key Molecule: Protein S100-A11 (S100A11) | [26] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell viability | Inhibition | hsa05200 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | miR-22 overexpression sensitizes MG-63 cells to cisplatin treatment and reduces the expression of S100A11. | |||
Key Molecule: Heat shock 70 kDa protein 1A (HSP70) | [27] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell viability | Inhibition | hsa05200 | ||
JNk signaling pathway | Activation | hsa04010 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
Sk-ES-1 cells | Bone | Homo sapiens (Human) | CVCL_0627 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | miR-223 overexpression could sensitize OS cell lines to CDDP and Hsp70 protein levels were remarkably reduced by miR-223 overexpression whereas increased by miR-223 inhibition. | |||
Key Molecule: Apoptosis regulator Bcl-2 (BCL2) | [30], [32] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
p53/p38/MAPK signaling pathway | Regulation | hsa04010 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
3AB-OS CSC cells | Bone marrow | Homo sapiens (Human) | CVCL_LM95 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
RT-PCR; Western blot analysis | |||
Experiment for Drug Resistance |
Trypan blue assay; Flow cytometry assay; CCK8 assay | |||
Mechanism Description | miR-29b-1 overexpression sensitized 3AB-OS cells to chemotherapeutic drug-induced apoptosis miR-29b-1 negatively regulated the expression of Bcl-2. Overexpression of miR-125b inhibited proliferation, migration, and invasion of OS cells and reduced the chemotherapy resistance of OS cells to cisplatin by targeting Bcl-2. | |||
Key Molecule: Protein sprouty homolog 2 (SPRY2) | [28] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell proliferation | Activation | hsa05200 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
143B cells | Bone | Homo sapiens (Human) | CVCL_2270 | |
HLNG cells | Bone marrow | Homo sapiens (Human) | N.A. | |
Experiment for Molecule Alteration |
Northern blotting | |||
Experiment for Drug Resistance |
Scratch assay | |||
Mechanism Description | miR-21 regulatory network plays a role in tumorigenesis of osteosarcoma. Its expression facilitates cell proliferation and decreases cellular sensitivity towards cisplatin. Both effects can be rescued by Spry2, a target protein downregulated by increased miR-21 levels. | |||
Key Molecule: Histone-lysine N-methyltransferase EZH2 (EZH2) | [29] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Inhibition | hsa05200 | |
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
miR138/EZH2 signaling pathway | Regulation | hsa05206 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
Experiment for Molecule Alteration |
Western blot analysis; Flow cytometric assay | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | miR-138 acts as a tumor suppressor in osteosarcoma, inhibiting cell proliferation, migration, and invasion by downregulating EZH2 expression. Mir-138 overexpression also enhances osteosarcoma cell chemosensitivity to cisplatin by targeting EZH2. | |||
Key Molecule: Homeodomain-interacting protein kinase 3 (HIPK3) | [31] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | Decreased miR-382 was associated with poor survival in OS patients. Overexpression of miR-382 inhibited cell growth and chemoresistance by targeting kLF12 and HIPk3, respectively. In contrast, inhibition of miR-382 or overexpression of target genes stimulated OS cell growth and chemoresistance both in vitro and in vivo. | |||
Key Molecule: Krueppel-like factor 12 (KLF12) | [31] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | Decreased miR-382 was associated with poor survival in OS patients. Overexpression of miR-382 inhibited cell growth and chemoresistance by targeting kLF12 and HIPk3, respectively. In contrast, inhibition of miR-382 or overexpression of target genes stimulated OS cell growth and chemoresistance both in vitro and in vivo. | |||
Key Molecule: DNA repair protein RAD51 homolog 1 (RAD51) | [33], [34] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
Survival assay/crystal violet staining assay | |||
Mechanism Description | miR-103 and miR-107 reduced homology-directed repair and sensitized cells to various DNA damaging agents, including cisplatin and a PARP inhibitor. Mechanistic analyses revealed that both miR-103 and miR-107 directly target and regulate RAD51 and RAD51D, which is critical for miR-103/107-mediated chemosensitization. And overexpression of miR-96 in human cancer cells reduces the levels of RAD51 and REV1 and impacts the cellular response to agents that cause DNA damage. | |||
Key Molecule: DNA repair protein RAD51 homolog 4 (RAD51D) | [33] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
Survival assay/crystal violet staining assay | |||
Mechanism Description | miR-103 and miR-107 reduced homology-directed repair and sensitized cells to various DNA damaging agents, including cisplatin and a PARP inhibitor. Mechanistic analyses revealed that both miR-103 and miR-107 directly target and regulate RAD51 and RAD51D, which is critical for miR-103/107-mediated chemosensitization. | |||
Key Molecule: DNA repair protein REV1 (REV1) | [34] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Cisplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
Flow cytometry assay | |||
Mechanism Description | Overexpression of miR-96 in human cancer cells reduces the levels of RAD51 and REV1 and impacts the cellular response to agents that cause DNA damage. |
Decitabine
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: Cyclin-dependent kinase inhibitor 2A (CDKN2A) | [35] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Decitabine | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell viability | Activation | hsa05200 | ||
HOTAIR-miR126-DNMT1-CDkN2A axis | Regulation | hsa05206 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
143B cells | Bone | Homo sapiens (Human) | CVCL_2270 | |
NHOst cells | Bone | Homo sapiens (Human) | N.A. | |
HFob 1.19 | Bone | Homo sapiens (Human) | CVCL_3708 | |
Experiment for Molecule Alteration |
RT-qPCR; ChIP assay | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | HOTAIR represses the expression of CDkN2A through inhibiting the promoter activity of CDkN2A by RNA hypermethylation. HOTAIR depletion increases the sensibility of OS cells to DNMT1 inhibitor through regulating the viability and apoptosis of OS cells via HOTAIR-miR126-DNMT1-CDkN2A axis. | |||
Key Molecule: HOX transcript antisense RNA (HOTAIR) | [35] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Decitabine | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell viability | Activation | hsa05200 | ||
HOTAIR-miR126-DNMT1-CDkN2A axis | Regulation | hsa05206 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
143B cells | Bone | Homo sapiens (Human) | CVCL_2270 | |
NHOst cells | Bone | Homo sapiens (Human) | N.A. | |
HFob 1.19 | Bone | Homo sapiens (Human) | CVCL_3708 | |
Experiment for Molecule Alteration |
qPCR | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | HOTAIR represses the expression of CDkN2A through inhibiting the promoter activity of CDkN2A by RNA hypermethylation. HOTAIR depletion increases the sensibility of OS cells to DNMT1 inhibitor through regulating the viability and apoptosis of OS cells via HOTAIR-miR126-DNMT1-CDkN2A axis. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: DNA (cytosine-5)-methyltransferase 1 (DNMT1) | [35] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Decitabine | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell viability | Activation | hsa05200 | ||
HOTAIR-miR126-DNMT1-CDkN2A axis | Regulation | hsa05206 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
143B cells | Bone | Homo sapiens (Human) | CVCL_2270 | |
NHOst cells | Bone | Homo sapiens (Human) | N.A. | |
HFob 1.19 | Bone | Homo sapiens (Human) | CVCL_3708 | |
Experiment for Molecule Alteration |
RT-qPCR; Western blot analysis; ChIP assay | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | HOTAIR activates the expression of DNMT1 through repressing miR126, which is the negative regulator of DNMT1. HOTAIR depletion increases the sensibility of OS cells to DNMT1 inhibitor through regulating the viability and apoptosis of OS cells via HOTAIR-miR126-DNMT1-CDkN2A axis. |
Doxorubicin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-mir-152 | [36] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell proliferation | Activation | hsa05200 | ||
c-Met/PI3K/AKT signaling pathway | Activation | hsa01521 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay; Soft agar assay | |||
Mechanism Description | LncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to doxorubicin through activating c-MET/PI3k/AkT pathway. | |||
Key Molecule: Pvt1 oncogene (PVT1) | [36] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell proliferation | Activation | hsa05200 | ||
c-Met/PI3K/AKT signaling pathway | Activation | hsa01521 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay; Soft agar assay | |||
Mechanism Description | LncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to doxorubicin through activating c-MET/PI3k/AkT pathway. | |||
Key Molecule: hsa-miR-34a-5p | [2], [6] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | ATF2/ATF3/ATF4 signaling pathway | Inhibition | hsa04915 | |
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Annexin V-FITC/propidium iodide (PI) staining assay | |||
Mechanism Description | The miR34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene. And miR34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene. | |||
Key Molecule: hsa-miR-20a-5p | [37] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | miR20a-5p modulates multi-drug resistance by repressing SDC2 expression in OS cells. | |||
Key Molecule: hsa-mir-375 | [38] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vivo Model | A retrospective survey in conducting clinical studies | Homo sapiens | ||
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
Multivariate analysis of overall survival or disease-free survival assay | |||
Mechanism Description | miR375 overexpression could increase the cisplatin sensitivity of human gastric cancer cells by regulating ERBB2. | |||
Key Molecule: hsa-miR-3182 | [39] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | ODRUL/miR3182/MMP2 signaling pathway | Regulation | hsa05206 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
143B cells | Bone | Homo sapiens (Human) | CVCL_2270 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Dual Luciferase Reporter Assay; PCR | |||
Experiment for Drug Resistance |
Wound Healing Assay; Colony Formation Assay; CCK8 Assay | |||
Mechanism Description | LncRNA ODRUL Contributes to Osteosarcoma Progression through the miR3182/MMP2 Axis. miR3182 expression and function are inversely correlated with ODRUL expression in vitro and in vivo, miR3182 negatively regulated the mRNA level and the protein level of MMP2 expression. ODRUL could directly interact with miR3182 and upregulate MMP2 expression via its competing endogenous RNA activity on miR3182 at the posttranscriptional level. | |||
Key Molecule: FOXC2 antisense RNA 1 (FOXC2-AS1) | [39] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | ODRUL/miR3182/MMP2 signaling pathway | Regulation | hsa05206 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
143B cells | Bone | Homo sapiens (Human) | CVCL_2270 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
PCR | |||
Experiment for Drug Resistance |
Wound Healing Assay; Colony Formation Assay; CCK8 Assay | |||
Mechanism Description | LncRNA ODRUL Contributes to Osteosarcoma Progression through the miR3182/MMP2 Axis. miR3182 expression and function are inversely correlated with ODRUL expression in vitro and in vivo, miR3182 negatively regulated the mRNA level and the protein level of MMP2 expression. ODRUL could directly interact with miR3182 and upregulate MMP2 expression via its competing endogenous RNA activity on miR3182 at the posttranscriptional level. | |||
Key Molecule: hsa-miR-140-5p | [40] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell autophagy | Activation | hsa04140 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
hFOB1.19 cells | Fetal bone | Homo sapiens (Human) | CVCL_3708 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
IC50 assay; Flow cytometric analysis | |||
Mechanism Description | miR140-5p/HMGN5/autophagy regulatory loop plays a critical role in chemoresistance in osteosarcoma, miR 140-5p regulates osteosarcoma chemoresistance by targeting HMGN5 and autophagy. | |||
Key Molecule: FOXC2 antisense RNA 1 (FOXC2-AS1) | [41] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay; Colony formation assay | |||
Mechanism Description | Antisense LncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2. FOXC2-AS1 contributes to doxorubicin resistance by increasing FOXC2 and further facilitating ABCB1. | |||
Key Molecule: Delta-like protein 1 (DLL1) | [6] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | ATF2/ATF3/ATF4 signaling pathway | Inhibition | hsa04915 | |
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
MG63.2 cells | Bone | Homo sapiens (Human) | CVCL_R705 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
IC50 assay; Flow cytometric analysis | |||
Mechanism Description | miR34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene. The activity of the ATF2/ATF3/ATF4 pathway was reduced in the miR34a-5p mimic-transfected G-292 cells but increased in the miR34a-5p antagomiRtransfected SJSA-1 cells, hence the ATF2/ATF3/ATF4 pathway was validated to be involved in the OS chemoresistance mediated by miR34a-5p. | |||
Key Molecule: Small nucleolar RNA host gene 12 (SNHG12) | [42] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell viability | Activation | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | The up-regulation of MCL1 reversed the sensitivity of doxorubicin induced by miR-320a mimics and knockdown of SNHG12. | |||
Key Molecule: hsa-mir-320 | [42] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell viability | Activation | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | The up-regulation of MCL1 reversed the sensitivity of doxorubicin induced by miR-320a mimics and knockdown of SNHG12. | |||
Key Molecule: hsa-miR-199a-3p | [3] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell viability | Activation | hsa05200 | |
NF-kappaB signaling pathway | Inhibition | hsa04064 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | The Ak4 gene is one of the targets of miR-199a-3p and negatively correlates with the effect of miR-199a-3p on OS drug-resistance. | |||
Key Molecule: hsa_circ_PVT1 | [9] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell colony | Activation | hsa05200 | |
Cell viability | Activation | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
KHOS cells | Bone | Homo sapiens (Human) | CVCL_2546 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay; Colony formation assay | |||
Mechanism Description | CircPVT1 knockdown reduces the expression of classical multidrug resistance related gene-ABCB1 in OS cells. | |||
Key Molecule: hsa-miR-184 | [43] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | AKT/BCL2 signaling pathway | Regulation | hsa04933 | |
Cell apoptosis | Activation | hsa04210 | ||
NF-kappaB signaling pathway | Regulation | hsa04064 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
Flow cytometry assay | |||
Mechanism Description | microRNA-184 modulates doxorubicin resistance in osteosarcoma cells by targeting BCL2L1 and enhancing the level of it. | |||
Key Molecule: hsa-miR-34a-5p | [4] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Activation | hsa05200 | |
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
MEF2 signaling pathway | Regulation | hsa04013 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 | |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
MG63.2 cells | Bone | Homo sapiens (Human) | CVCL_R705 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | The down-regulation of CD117 mediated by miR-34a-5p might be one of the reasons for OS drug resistance. CD117 may also regulate other processes, including cell adhesion, differentiation and migration, which are significant for cancer development and treatment. | |||
Key Molecule: hsa-mir-30a | [44] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | Down-regulation of miR-30a contributed to chemoresistance of osteosarcoma cells through regulating autophagy. Furthermore, to investigate the mechanism of miR-130a in regulating autophagy, bioinformatics analysis was performed. The results showed that the 3'-UTR region of Beclin-1 were the binding sites for miR-30a. Consistently, previous studies demonstrated that Beclin-1 was the directly target of miR-30a. | |||
Key Molecule: hsa-miR-146b-5p | [11] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell proliferation | Activation | hsa05200 | ||
Cell viability | Activation | hsa05200 | ||
Wnt/Beta-catenin signaling pathway | Regulation | hsa04310 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
hFOB1.19 cells | Fetal bone | Homo sapiens (Human) | CVCL_3708 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | miR-146b-5p was highly expressed in human osteosarcoma tissues and an elevated expression of miR-146b-5p was observed in human osteosarcoma tissues after chemotherapy. Furthermore, it was shown that miR-146b-5p overexpression promoted migration and invasiveness. miR-146b-5p overexpression also increased resistance to chemotherapy. Moreover, knockdown of miR-146b-5p substantially inhibited migration and invasion of osteosarcoma cells as well as rendered them significantly more sensitive to chemotherapy. Results of western blot assay indicated that miR-146b-5p increased MMP-16 protein expression and showed a decrease of ZNRF3 protein. Whereas, IWR-1-endo, an inhibitor of Wnt/beta-catenin, suppressed the decrease in apoptosis of osteosarcoma cells caused by miR-146b-5p overexpression. These results indicated that miR-146b-5p promoted proliferation, migration and invasiveness. | |||
Key Molecule: hsa-mir-143 | [45] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
In Vivo Model | NOD-SCID IL2-rgamma -null (NSG) mouse engraftment model | Mus musculus | ||
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Matrigel colony formation assay; Hoechst33342 staining assay | |||
Mechanism Description | In chemoresistant SAOS-2 and U2OS osteosarcomas cells, miR-143 levels were significantly downregulated and accompanied by increases in ATG2B, Bcl-2, and/or LC3-II protein levels, high rate of ALDH1+CD133+ cells, and an increase in Matrigel colony formation ability. H2O2 upregulated p53 and miR-143, but downregulated ATG2B, Bcl-2, and LC3-I expression in U2OS cells (wild-type p53) but not in SAOS-2 (p53-null) cells. Forced miR-143 expression significantly reversed chemoresistance as well as downregulation of ATG2B, LC3-I, and Bcl-2 expression in SAOS-2- and U2OS-resistant cells. Forced miR-143 expression significantly inhibited tumor growth in xenograft SAOS-2-Dox and U2OS-Dox animal models. Loss of miR-143 expression is associated with poor prognosis of patients with osteosarcoma underlying chemotherapy. The chemoresistance of osteosarcoma tumor cells to doxorubicin is associated with the downregulation of miR-143 expression, activation of ALDH1+CD133+ cells, activation of autophagy, and inhibition of cell death. | |||
Key Molecule: hsa-mir-155 | [46] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell proliferation | Activation | hsa05200 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qPCR | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | During treatment with Dox or Cis in osteosarcoma cells, miR-155 expression was strongly induced. The increased miR-155 expression facilitated tumor cell proliferation via upregulating autophagy, thus, facilitated the resistance of osteosarcoma cells to Dox or Cis. | |||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: Multidrug resistance protein 1 (ABCB1) | [9] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell colony | Activation | hsa05200 | |
Cell viability | Activation | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
KHOS cells | Bone | Homo sapiens (Human) | CVCL_2546 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay; Colony formation assay | |||
Mechanism Description | CircPVT1 knockdown reduces the expression of classical multidrug resistance related gene-ABCB1 in OS cells. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Syndecan-2 (SDC2) | [37] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
Experiment for Molecule Alteration |
Luciferase reporter assay; Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | miR20a-5p modulates multi-drug resistance by repressing SDC2 expression in OS cells. | |||
Key Molecule: Nucleosome-binding protein 1 (NSBP1) | [40] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell autophagy | Activation | hsa04140 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
hFOB1.19 cells | Fetal bone | Homo sapiens (Human) | CVCL_3708 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Luciferase activity assay; Western blot analysis | |||
Experiment for Drug Resistance |
IC50 assay; Flow cytometric analysis | |||
Mechanism Description | miR140-5p/HMGN5/autophagy regulatory loop plays a critical role in chemoresistance in osteosarcoma, miR 140-5p regulates osteosarcoma chemoresistance by targeting HMGN5 and autophagy. | |||
Key Molecule: Forkhead box protein C2 (FOXC2) | [41] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay; Colony formation assay | |||
Mechanism Description | Antisense LncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2. FOXC2-AS1 contributes to doxorubicin resistance by increasing FOXC2 and further facilitating ABCB1. | |||
Key Molecule: Type-1 angiotensin II receptor (AGTR1) | [2] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay; Annexin V-FITC/propidium iodide (PI) staining assay | |||
Mechanism Description | The miR34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene. | |||
Key Molecule: Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) | [42] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell viability | Activation | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | The up-regulation of MCL1 reversed the sensitivity of doxorubicin induced by miR-320a mimics and knockdown of SNHG12. | |||
Key Molecule: Adenylate kinase 4 (AK4) | [3] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell viability | Activation | hsa05200 | |
NF-kappaB signaling pathway | Inhibition | hsa04064 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis; RIP assay; Luciferase reporter assay | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | The Ak4 gene is one of the targets of miR-199a-3p and negatively correlates with the effect of miR-199a-3p on OS drug-resistance. | |||
Key Molecule: Bcl-2-like protein 11 (BCL2L11) | [43] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | AKT/BCL2 signaling pathway | Regulation | hsa04933 | |
Cell apoptosis | Activation | hsa04210 | ||
NF-kappaB signaling pathway | Regulation | hsa04064 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
Flow cytometry assay | |||
Mechanism Description | microRNA-184 modulates doxorubicin resistance in osteosarcoma cells by targeting BCL2L1 and enhancing the level of it. | |||
Key Molecule: Mast/stem cell growth factor receptor Kit (KIT) | [4] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Activation | hsa05200 | |
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
MEF2 signaling pathway | Regulation | hsa04013 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 | |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
MG63.2 cells | Bone | Homo sapiens (Human) | CVCL_R705 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | The down-regulation of CD117 mediated by miR-34a-5p might be one of the reasons for OS drug resistance. CD117 may also regulate other processes, including cell adhesion, differentiation and migration, which are significant for cancer development and treatment. | |||
Key Molecule: Beclin-1 (BECN1) | [44] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | Down-regulation of miR-30a contributed to chemoresistance of osteosarcoma cells through regulating autophagy. Furthermore, to investigate the mechanism of miR-130a in regulating autophagy, bioinformatics analysis was performed. The results showed that the 3'-UTR region of Beclin-1 were the binding sites for miR-30a. Consistently, previous studies demonstrated that Beclin-1 was the directly target of miR-30a. | |||
Key Molecule: E3 ubiquitin-protein ligase ZNRF3 (ZNRF3) | [11] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell invasion | Activation | hsa05200 | ||
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
Wnt/Beta-catenin signaling pathway | Regulation | hsa04310 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
hFOB1.19 cells | Fetal bone | Homo sapiens (Human) | CVCL_3708 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | miR-146b-5p was highly expressed in human osteosarcoma tissues and an elevated expression of miR-146b-5p was observed in human osteosarcoma tissues after chemotherapy. Furthermore, it was shown that miR-146b-5p overexpression promoted migration and invasiveness. miR-146b-5p overexpression also increased resistance to chemotherapy. Moreover, knockdown of miR-146b-5p substantially inhibited migration and invasion of osteosarcoma cells as well as rendered them significantly more sensitive to chemotherapy. Results of western blot assay indicated that miR-146b-5p increased MMP-16 protein expression and showed a decrease of ZNRF3 protein. Whereas, IWR-1-endo, an inhibitor of Wnt/beta-catenin, suppressed the decrease in apoptosis of osteosarcoma cells caused by miR-146b-5p overexpression. These results indicated that miR-146b-5p promoted proliferation, migration and invasiveness. | |||
Key Molecule: Autophagy-related protein 2 homolog B (ATG2B) | [45] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay; Matrigel colony formation assay; Hoechst33342 staining assay | |||
Mechanism Description | In chemoresistant SAOS-2 and U2OS osteosarcomas cells, miR-143 levels were significantly downregulated and accompanied by increases in ATG2B, Bcl-2, and/or LC3-II protein levels, high rate of ALDH1+CD133+ cells, and an increase in Matrigel colony formation ability. H2O2 upregulated p53 and miR-143, but downregulated ATG2B, Bcl-2, and LC3-I expression in U2OS cells (wild-type p53) but not in SAOS-2 (p53-null) cells. Forced miR-143 expression significantly reversed chemoresistance as well as downregulation of ATG2B, LC3-I, and Bcl-2 expression in SAOS-2- and U2OS-resistant cells. Forced miR-143 expression significantly inhibited tumor growth in xenograft SAOS-2-Dox and U2OS-Dox animal models. Loss of miR-143 expression is associated with poor prognosis of patients with osteosarcoma underlying chemotherapy. The chemoresistance of osteosarcoma tumor cells to doxorubicin is associated with the downregulation of miR-143 expression, activation of ALDH1+CD133+ cells, activation of autophagy, and inhibition of cell death. | |||
Key Molecule: Apoptosis regulator Bcl-2 (BCL2) | [45] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay; Matrigel colony formation assay; Hoechst33342 staining assay | |||
Mechanism Description | In chemoresistant SAOS-2 and U2OS osteosarcomas cells, miR-143 levels were significantly downregulated and accompanied by increases in ATG2B, Bcl-2, and/or LC3-II protein levels, high rate of ALDH1+CD133+ cells, and an increase in Matrigel colony formation ability. H2O2 upregulated p53 and miR-143, but downregulated ATG2B, Bcl-2, and LC3-I expression in U2OS cells (wild-type p53) but not in SAOS-2 (p53-null) cells. Forced miR-143 expression significantly reversed chemoresistance as well as downregulation of ATG2B, LC3-I, and Bcl-2 expression in SAOS-2- and U2OS-resistant cells. Forced miR-143 expression significantly inhibited tumor growth in xenograft SAOS-2-Dox and U2OS-Dox animal models. Loss of miR-143 expression is associated with poor prognosis of patients with osteosarcoma underlying chemotherapy. The chemoresistance of osteosarcoma tumor cells to doxorubicin is associated with the downregulation of miR-143 expression, activation of ALDH1+CD133+ cells, activation of autophagy, and inhibition of cell death. | |||
Key Molecule: Microtubule-associated proteins 1A/1B light chain 3A (MAP1LC3A) | [45] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay; Matrigel colony formation assay; Hoechst33342 staining assay | |||
Mechanism Description | In chemoresistant SAOS-2 and U2OS osteosarcomas cells, miR-143 levels were significantly downregulated and accompanied by increases in ATG2B, Bcl-2, and/or LC3-II protein levels, high rate of ALDH1+CD133+ cells, and an increase in Matrigel colony formation ability. H2O2 upregulated p53 and miR-143, but downregulated ATG2B, Bcl-2, and LC3-I expression in U2OS cells (wild-type p53) but not in SAOS-2 (p53-null) cells. Forced miR-143 expression significantly reversed chemoresistance as well as downregulation of ATG2B, LC3-I, and Bcl-2 expression in SAOS-2- and U2OS-resistant cells. Forced miR-143 expression significantly inhibited tumor growth in xenograft SAOS-2-Dox and U2OS-Dox animal models. Loss of miR-143 expression is associated with poor prognosis of patients with osteosarcoma underlying chemotherapy. The chemoresistance of osteosarcoma tumor cells to doxorubicin is associated with the downregulation of miR-143 expression, activation of ALDH1+CD133+ cells, activation of autophagy, and inhibition of cell death. |
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: FOXF1 adjacent non-coding developmental regulatory RNA (FENDRR) | [47] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qPCR; Microarray assay | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometric analysis | |||
Mechanism Description | LncRNA FENDRR sensitizes doxorubicin-resistance of osteosarcoma cells through down-regulating ABCB1 and ABCC1. | |||
Key Molecule: hsa-mir-100 | [48] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell growth | Inhibition | hsa05200 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
Experiment for Molecule Alteration |
RT-qPCR | |||
Experiment for Drug Resistance |
MTT assay; CCK8 assay | |||
Mechanism Description | Either ZNRF2 overexpression or miR100 depletion increased in vitro OS cell growth and improved cell survival at the presence of Doxorubicin. miR100 bindS to the 3'-UTR of ZNRF2 mRNA to prevent its protein translation, re-expression of miR100 may inhibit OS cell growth and decrease OS cell chemo-resistance. | |||
Key Molecule: Phosphate cytidylyltransferase 1A, choline (PCYT1A) | [49] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
TUNEL Assay; MTT assay; Flow cytometric analysis | |||
Mechanism Description | LncRNA CTA-miR210 axis plays an important role in reducing OS chemoresistance. LncRNA CTA could be activated by doxorubicin (DOX), and could promote OS cell apoptosis by competitively binding miR210, while inhibit cell autophagy. | |||
Key Molecule: hsa-mir-210 | [49] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR; Dual luciferase reporter assay | |||
Experiment for Drug Resistance |
TUNEL Assay; MTT assay; Flow cytometric analysis | |||
Mechanism Description | LncRNA CTA-miR210 axis plays an important role in reducing OS chemoresistance. LncRNA CTA could be activated by doxorubicin (DOX), and could promote OS cell apoptosis by competitively binding miR210, while inhibit cell autophagy. | |||
Key Molecule: hsa-mir-410 | [20] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | HEK293T cells | Kidney | Homo sapiens (Human) | CVCL_0063 |
MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HFob 1.19 | Bone | Homo sapiens (Human) | CVCL_3708 | |
Experiment for Molecule Alteration |
RT-qPCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | microRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma, miR410 directly decreased ATG16L1 expression by targeting its 3'-untranslated region. | |||
Key Molecule: hsa-mir-124 | [50] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
PI3K/AKT signaling pathway | Inhibition | hsa04151 | ||
In Vitro Model | MDA-MB-231 cells | Breast | Homo sapiens (Human) | CVCL_0062 |
T47D cells | Breast | Homo sapiens (Human) | CVCL_0553 | |
ZR75-1 cells | Breast | Homo sapiens (Human) | CVCL_0588 | |
HCC1937 cells | Breast | Homo sapiens (Human) | CVCL_0290 | |
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR-124 may be involved in DNA repair by directly targeting ATMIN and PARP1, suggesting that multiple DNA repair pathways are affected by miR-124 and therefore manipulation of miR-124 level/activity may improve the efficacy of chemotherapies that induce DNA damage. repression of ATMIN (+) the HR repair defect induced by miR-124, and restoration of ATMIN reversed the effect of miR-124 overexpression in breast cancer cells. Therefore, it is intriguing to further speculate which of the multiple roles of ATMIN is specifically affected in breast carcinogenesis. On the other hand, PARP1-mediated processes play a role in oncogenesis, cancer progression, and therapeutic resistance. | |||
Key Molecule: hsa-miR-199a-3p | [51] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell migration | Inhibition | hsa04670 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
KHOS cells | Bone | Homo sapiens (Human) | CVCL_2546 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | CD44 was overexpressed in metastatic and recurrent osteosarcoma as compared with primary tumors. Higher expression of CD44 was found in both patients with shorter survival and patients who exhibited unfavorable response to chemotherapy before surgical resection. Additionally, the 3'-untranslated region of CD44 mRNA was the direct target of microRNA-199a-3p (miR-199a-3p). Overexpression of miR-199a-3p significantly inhibited CD44 expression in osteosarcoma cells. miR-199a-3p is One of the most dramatically decreased miRs in osteosarcoma cells and tumor tissues as compared with normal osteoblast cells. Transfection of miR-199a-3p significantly increased the drug sensitivity through down-regulation of CD44 in osteosarcoma cells. Taken together, these results suggest that the CD44-miR-199a-3p axis plays an important role in the development of metastasis, recurrence, and drug resistance of osteosarcoma. Developing strategies to target CD44 may improve the clinical outcome of osteosarcoma. | |||
Key Molecule: hsa-mir-382 | [31] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | Decreased miR-382 was associated with poor survival in OS patients. Overexpression of miR-382 inhibited cell growth and chemoresistance by targeting kLF12 and HIPk3, respectively. In contrast, inhibition of miR-382 or overexpression of target genes stimulated OS cell growth and chemoresistance both in vitro and in vivo. | |||
Key Molecule: hsa-mir-101 | [52] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell proliferation | Inhibition | hsa05200 | |
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
Experiment for Molecule Alteration |
Quantitative GFP-LC3 analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | The miR-101 not only decreases the formation of autophagic vesicles but also reduces the expression of LC-3II and Atg 4. This part of the study shows that miR-101 blocks chemotherapy-induced autophagy in OS cells. The sensitivity of OS cells to chemotherapy is increased by miR-101 blocked autophagy. miR-101 blocked the chemotherapy induced autophagy, and the blocked autophagy by miR-101 enhances the sensitivity of the OS cell line U-2 in vitro. | |||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: Multidrug resistance protein 1 (ABCB1) | [47] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometric analysis | |||
Mechanism Description | LncRNA FENDRR sensitizes doxorubicin-resistance of osteosarcoma cells through down-regulating ABCB1 and ABCC1. | |||
Key Molecule: Multidrug resistance-associated protein 1 (MRP1) | [47] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometric analysis | |||
Mechanism Description | LncRNA FENDRR sensitizes doxorubicin-resistance of osteosarcoma cells through down-regulating ABCB1 and ABCC1. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: E3 ubiquitin-protein ligase ZNRF2 (ZNRF2) | [48] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell growth | Inhibition | hsa05200 | |
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
Experiment for Molecule Alteration |
Western blot analysis; Luciferase reporter assay | |||
Experiment for Drug Resistance |
MTT assay; CCK8 assay | |||
Mechanism Description | Either ZNRF2 overexpression or miR100 depletion increased in vitro OS cell growth and improved cell survival at the presence of Doxorubicin. miR100 bindS to the 3'-UTR of ZNRF2 mRNA to prevent its protein translation, re-expression of miR100 may inhibit OS cell growth and decrease OS cell chemo-resistance. | |||
Key Molecule: Autophagy-related protein 16-1 (ATG16L1) | [20] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | HEK293T cells | Kidney | Homo sapiens (Human) | CVCL_0063 |
MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HFob 1.19 | Bone | Homo sapiens (Human) | CVCL_3708 | |
Experiment for Molecule Alteration |
Luciferase reporter assay; Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | microRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma, miR410 directly decreased ATG16L1 expression by targeting its 3'-untranslated region. | |||
Key Molecule: ATM interactor (ATMIN) | [50] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
PI3K/AKT signaling pathway | Inhibition | hsa04151 | ||
In Vitro Model | MDA-MB-231 cells | Breast | Homo sapiens (Human) | CVCL_0062 |
T47D cells | Breast | Homo sapiens (Human) | CVCL_0553 | |
ZR75-1 cells | Breast | Homo sapiens (Human) | CVCL_0588 | |
HCC1937 cells | Breast | Homo sapiens (Human) | CVCL_0290 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR-124 may be involved in DNA repair by directly targeting ATMIN and PARP1, suggesting that multiple DNA repair pathways are affected by miR-124 and therefore manipulation of miR-124 level/activity may improve the efficacy of chemotherapies that induce DNA damage. repression of ATMIN (+) the HR repair defect induced by miR-124, and restoration of ATMIN reversed the effect of miR-124 overexpression in breast cancer cells. Therefore, it is intriguing to further speculate which of the multiple roles of ATMIN is specifically affected in breast carcinogenesis. On the other hand, PARP1-mediated processes play a role in oncogenesis, cancer progression, and therapeutic resistance. | |||
Key Molecule: Poly[ADP-ribose] synthase 1 (PARP1) | [50] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
PI3K/AKT signaling pathway | Inhibition | hsa04151 | ||
In Vitro Model | MDA-MB-231 cells | Breast | Homo sapiens (Human) | CVCL_0062 |
T47D cells | Breast | Homo sapiens (Human) | CVCL_0553 | |
ZR75-1 cells | Breast | Homo sapiens (Human) | CVCL_0588 | |
HCC1937 cells | Breast | Homo sapiens (Human) | CVCL_0290 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR-124 may be involved in DNA repair by directly targeting ATMIN and PARP1, suggesting that multiple DNA repair pathways are affected by miR-124 and therefore manipulation of miR-124 level/activity may improve the efficacy of chemotherapies that induce DNA damage. repression of ATMIN (+) the HR repair defect induced by miR-124, and restoration of ATMIN reversed the effect of miR-124 overexpression in breast cancer cells. Therefore, it is intriguing to further speculate which of the multiple roles of ATMIN is specifically affected in breast carcinogenesis. On the other hand, PARP1-mediated processes play a role in oncogenesis, cancer progression, and therapeutic resistance. | |||
Key Molecule: Extracellular matrix receptor III (CD44) | [51] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell migration | Inhibition | hsa04670 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
KHOS cells | Bone | Homo sapiens (Human) | CVCL_2546 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | CD44 was overexpressed in metastatic and recurrent osteosarcoma as compared with primary tumors. Higher expression of CD44 was found in both patients with shorter survival and patients who exhibited unfavorable response to chemotherapy before surgical resection. Additionally, the 3'-untranslated region of CD44 mRNA was the direct target of microRNA-199a-3p (miR-199a-3p). Overexpression of miR-199a-3p significantly inhibited CD44 expression in osteosarcoma cells. miR-199a-3p is One of the most dramatically decreased miRs in osteosarcoma cells and tumor tissues as compared with normal osteoblast cells. Transfection of miR-199a-3p significantly increased the drug sensitivity through down-regulation of CD44 in osteosarcoma cells. Taken together, these results suggest that the CD44-miR-199a-3p axis plays an important role in the development of metastasis, recurrence, and drug resistance of osteosarcoma. Developing strategies to target CD44 may improve the clinical outcome of osteosarcoma. | |||
Key Molecule: Homeodomain-interacting protein kinase 3 (HIPK3) | [31] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | Decreased miR-382 was associated with poor survival in OS patients. Overexpression of miR-382 inhibited cell growth and chemoresistance by targeting kLF12 and HIPk3, respectively. In contrast, inhibition of miR-382 or overexpression of target genes stimulated OS cell growth and chemoresistance both in vitro and in vivo. | |||
Key Molecule: Krueppel-like factor 12 (KLF12) | [31] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | Decreased miR-382 was associated with poor survival in OS patients. Overexpression of miR-382 inhibited cell growth and chemoresistance by targeting kLF12 and HIPk3, respectively. In contrast, inhibition of miR-382 or overexpression of target genes stimulated OS cell growth and chemoresistance both in vitro and in vivo. | |||
Key Molecule: Ubiquitin-like modifier-activating enzyme Atg 4 (ATG4) | [52] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell proliferation | Inhibition | hsa05200 | |
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | The miR-101 not only decreases the formation of autophagic vesicles but also reduces the expression of LC-3II and Atg 4. This part of the study shows that miR-101 blocks chemotherapy-induced autophagy in OS cells. The sensitivity of OS cells to chemotherapy is increased by miR-101 blocked autophagy. miR-101 blocked the chemotherapy induced autophagy, and the blocked autophagy by miR-101 enhances the sensitivity of the OS cell line U-2 in vitro. | |||
Key Molecule: Microtubule-associated protein 1 light chain3 (LC3) | [52] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Doxorubicin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell proliferation | Inhibition | hsa05200 | |
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | The miR-101 not only decreases the formation of autophagic vesicles but also reduces the expression of LC-3II and Atg 4. This part of the study shows that miR-101 blocks chemotherapy-induced autophagy in OS cells. The sensitivity of OS cells to chemotherapy is increased by miR-101 blocked autophagy. miR-101 blocked the chemotherapy induced autophagy, and the blocked autophagy by miR-101 enhances the sensitivity of the OS cell line U-2 in vitro. |
Etoposide
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-miR-34a-5p | [2], [6] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Etoposide | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | ATF2/ATF3/ATF4 signaling pathway | Inhibition | hsa04915 | |
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Annexin V-FITC/propidium iodide (PI) staining assay | |||
Mechanism Description | The miR34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene. And miR34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene. | |||
Key Molecule: hsa-miR-20a-5p | [37] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Etoposide | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | miR20a-5p modulates multi-drug resistance by repressing SDC2 expression in OS cells. | |||
Key Molecule: Delta-like protein 1 (DLL1) | [6] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Etoposide | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | ATF2/ATF3/ATF4 signaling pathway | Inhibition | hsa04915 | |
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
MG63.2 cells | Bone | Homo sapiens (Human) | CVCL_R705 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
IC50 assay; Flow cytometric analysis | |||
Mechanism Description | miR34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene. The activity of the ATF2/ATF3/ATF4 pathway was reduced in the miR34a-5p mimic-transfected G-292 cells but increased in the miR34a-5p antagomiRtransfected SJSA-1 cells, hence the ATF2/ATF3/ATF4 pathway was validated to be involved in the OS chemoresistance mediated by miR34a-5p. | |||
Key Molecule: hsa-miR-34a-5p | [4] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Etoposide | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Activation | hsa05200 | |
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
MEF2 signaling pathway | Regulation | hsa04013 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 | |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
MG63.2 cells | Bone | Homo sapiens (Human) | CVCL_R705 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | The down-regulation of CD117 mediated by miR-34a-5p might be one of the reasons for OS drug resistance. CD117 may also regulate other processes, including cell adhesion, differentiation and migration, which are significant for cancer development and treatment. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Syndecan-2 (SDC2) | [37] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Etoposide | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
Experiment for Molecule Alteration |
Luciferase reporter assay; Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | miR20a-5p modulates multi-drug resistance by repressing SDC2 expression in OS cells. | |||
Key Molecule: Type-1 angiotensin II receptor (AGTR1) | [2] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Etoposide | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay; Annexin V-FITC/propidium iodide (PI) staining assay | |||
Mechanism Description | The miR34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene. | |||
Key Molecule: Mast/stem cell growth factor receptor Kit (KIT) | [4] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Etoposide | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Activation | hsa05200 | |
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
MEF2 signaling pathway | Regulation | hsa04013 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 | |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
MG63.2 cells | Bone | Homo sapiens (Human) | CVCL_R705 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | The down-regulation of CD117 mediated by miR-34a-5p might be one of the reasons for OS drug resistance. CD117 may also regulate other processes, including cell adhesion, differentiation and migration, which are significant for cancer development and treatment. |
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-mir-124 | [50] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Etoposide | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
PI3K/AKT signaling pathway | Inhibition | hsa04151 | ||
In Vitro Model | MDA-MB-231 cells | Breast | Homo sapiens (Human) | CVCL_0062 |
T47D cells | Breast | Homo sapiens (Human) | CVCL_0553 | |
ZR75-1 cells | Breast | Homo sapiens (Human) | CVCL_0588 | |
HCC1937 cells | Breast | Homo sapiens (Human) | CVCL_0290 | |
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR-124 may be involved in DNA repair by directly targeting ATMIN and PARP1, suggesting that multiple DNA repair pathways are affected by miR-124 and therefore manipulation of miR-124 level/activity may improve the efficacy of chemotherapies that induce DNA damage. repression of ATMIN (+) the HR repair defect induced by miR-124, and restoration of ATMIN reversed the effect of miR-124 overexpression in breast cancer cells. Therefore, it is intriguing to further speculate which of the multiple roles of ATMIN is specifically affected in breast carcinogenesis. On the other hand, PARP1-mediated processes play a role in oncogenesis, cancer progression, and therapeutic resistance. | |||
Key Molecule: hsa-mir-103 | [33] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Etoposide | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
Survival assay/crystal violet staining assay | |||
Mechanism Description | miR-103 and miR-107 reduced homology-directed repair and sensitized cells to various DNA damaging agents, including cisplatin and a PARP inhibitor. Mechanistic analyses revealed that both miR-103 and miR-107 directly target and regulate RAD51 and RAD51D, which is critical for miR-103/107-mediated chemosensitization. | |||
Key Molecule: hsa-miR-107 | [33] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Etoposide | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
Survival assay/crystal violet staining assay | |||
Mechanism Description | miR-103 and miR-107 reduced homology-directed repair and sensitized cells to various DNA damaging agents, including cisplatin and a PARP inhibitor. Mechanistic analyses revealed that both miR-103 and miR-107 directly target and regulate RAD51 and RAD51D, which is critical for miR-103/107-mediated chemosensitization. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: ATM interactor (ATMIN) | [50] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Etoposide | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
PI3K/AKT signaling pathway | Inhibition | hsa04151 | ||
In Vitro Model | MDA-MB-231 cells | Breast | Homo sapiens (Human) | CVCL_0062 |
T47D cells | Breast | Homo sapiens (Human) | CVCL_0553 | |
ZR75-1 cells | Breast | Homo sapiens (Human) | CVCL_0588 | |
HCC1937 cells | Breast | Homo sapiens (Human) | CVCL_0290 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR-124 may be involved in DNA repair by directly targeting ATMIN and PARP1, suggesting that multiple DNA repair pathways are affected by miR-124 and therefore manipulation of miR-124 level/activity may improve the efficacy of chemotherapies that induce DNA damage. repression of ATMIN (+) the HR repair defect induced by miR-124, and restoration of ATMIN reversed the effect of miR-124 overexpression in breast cancer cells. Therefore, it is intriguing to further speculate which of the multiple roles of ATMIN is specifically affected in breast carcinogenesis. On the other hand, PARP1-mediated processes play a role in oncogenesis, cancer progression, and therapeutic resistance. | |||
Key Molecule: Poly[ADP-ribose] synthase 1 (PARP1) | [50] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Etoposide | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
PI3K/AKT signaling pathway | Inhibition | hsa04151 | ||
In Vitro Model | MDA-MB-231 cells | Breast | Homo sapiens (Human) | CVCL_0062 |
T47D cells | Breast | Homo sapiens (Human) | CVCL_0553 | |
ZR75-1 cells | Breast | Homo sapiens (Human) | CVCL_0588 | |
HCC1937 cells | Breast | Homo sapiens (Human) | CVCL_0290 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR-124 may be involved in DNA repair by directly targeting ATMIN and PARP1, suggesting that multiple DNA repair pathways are affected by miR-124 and therefore manipulation of miR-124 level/activity may improve the efficacy of chemotherapies that induce DNA damage. repression of ATMIN (+) the HR repair defect induced by miR-124, and restoration of ATMIN reversed the effect of miR-124 overexpression in breast cancer cells. Therefore, it is intriguing to further speculate which of the multiple roles of ATMIN is specifically affected in breast carcinogenesis. On the other hand, PARP1-mediated processes play a role in oncogenesis, cancer progression, and therapeutic resistance. | |||
Key Molecule: E2F1-regulated inhibitor of cell death (ERICD) | [53] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Etoposide | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
Fluorescence-activated cell sorting analysis | |||
Mechanism Description | The long non-coding RNA ERIC is regulated by E2F and modulates the cellular response to DNA damage, ERIC levels were increased following DNA damage by the chemotherapeutic drug Etoposide, and inhibition of ERIC expression enhanced Etoposide -induced apoptosis. | |||
Key Molecule: DNA repair protein RAD51 homolog 1 (RAD51) | [33] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Etoposide | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
Survival assay/crystal violet staining assay | |||
Mechanism Description | miR-103 and miR-107 reduced homology-directed repair and sensitized cells to various DNA damaging agents, including cisplatin and a PARP inhibitor. Mechanistic analyses revealed that both miR-103 and miR-107 directly target and regulate RAD51 and RAD51D, which is critical for miR-103/107-mediated chemosensitization. | |||
Key Molecule: DNA repair protein RAD51 homolog 4 (RAD51D) | [33] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Etoposide | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
Survival assay/crystal violet staining assay | |||
Mechanism Description | miR-103 and miR-107 reduced homology-directed repair and sensitized cells to various DNA damaging agents, including cisplatin and a PARP inhibitor. Mechanistic analyses revealed that both miR-103 and miR-107 directly target and regulate RAD51 and RAD51D, which is critical for miR-103/107-mediated chemosensitization. |
Fluorouracil
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-mir-140 | [54] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Fluorouracil | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell proliferation | Inhibition | hsa05200 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
WST-1 assay | |||
Mechanism Description | miR-140 is involved in the chemoresistance by reduced cell proliferation via G1 and G2 phase arrest mediated in part. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Histone deacetylase 4 (HDAC4) | [54] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Fluorouracil | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell proliferation | Inhibition | hsa05200 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
Western blotting analysis; Immunofluorescence analysis | |||
Experiment for Drug Resistance |
WST-1 assay | |||
Mechanism Description | miR-140 is involved in the chemoresistance by reduced cell proliferation via G1 and G2 phase arrest mediated in part. |
Gemcitabine
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-mir-152 | [36] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Gemcitabine | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell proliferation | Activation | hsa05200 | ||
c-Met/PI3K/AKT signaling pathway | Activation | hsa01521 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay; Soft agar assay | |||
Mechanism Description | LncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3k/AkT pathway. | |||
Key Molecule: Pvt1 oncogene (PVT1) | [36] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Gemcitabine | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell proliferation | Activation | hsa05200 | ||
c-Met/PI3K/AKT signaling pathway | Activation | hsa01521 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay; Soft agar assay | |||
Mechanism Description | LncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3k/AkT pathway. |
Ifosfamide
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Tripartite motif containing 37 (TRIM37) | [55] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Ifosfamide | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Wnt/Beta-catenin signaling pathway | Activation | hsa04310 | |
In Vitro Model | Saccharomyces cerevisiae strain BY4742 | 4932 | ||
SH-1-V6 cells | Esophagus | Homo sapiens (Human) | N.A. | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Mechanism Description | High expression of TRIM37 mRNA and protein was observed in paediatric osteosarcoma tumour samples. Treatment of cell lines Saos-2 and MG-63 with ifosfamide, doxorubicin, cisplatin, or methotrexate induced TRIM37 expression. Upregulation of TRIM37 in vitro induced drug resistance, whereas TRIM37 knockdown restored chemosensitivity. The TRIM37-induced chemoresistance was found to be partially dependent on the activation of the Wnt/beta-catenin signalling pathway. |
Lobaplatin
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Far upstream element-binding protein 1 (FUBP1) | [56] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Lobaplatin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | PC-3 cells | Prostate | Homo sapiens (Human) | CVCL_0035 |
SH-1-V6 cells | Esophagus | Homo sapiens (Human) | N.A. | |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | FUBP1 knockdown conferred lobaplatin sensitivity of osteosarcoma SaOS-2 Cells. |
Methotrexate
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: Lung cancer associated transcript 1 (LUCAT1) | [57] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Methotrexate | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Activation | hsa05200 | |
Cell proliferation | Activation | hsa05200 | ||
LUCAT1/miR200c/ABCB1 pathway | Regulation | hsa05206 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
HFOB cells | Bone | Homo sapiens (Human) | CVCL_3708 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qPCR | |||
Experiment for Drug Resistance |
CCK8 assay; Transwell invasion assay | |||
Mechanism Description | The modulation of LUCAT1 on ABCB1 through sponging miR200c. LncRNA LUCAT1 knockdown suppress the expression levels drug resistance related genes, proliferation, invasion and tumor growth of osteosarcoma cells in vitro and vivo, hence, LUCAT1 upregulation leads to improved chemoresistance. | |||
Key Molecule: hsa-mir-200c | [57] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Methotrexate | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Activation | hsa05200 | |
Cell proliferation | Activation | hsa05200 | ||
LUCAT1/miR200c/ABCB1 pathway | Regulation | hsa05206 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
HFOB cells | Bone | Homo sapiens (Human) | CVCL_3708 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay; Transwell invasion assay | |||
Mechanism Description | Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR200c/ABCB1 axis. | |||
Key Molecule: hsa-mir-375 | [38] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Methotrexate | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vivo Model | A retrospective survey in conducting clinical studies | Homo sapiens | ||
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
Multivariate analysis of overall survival or disease-free survival assay | |||
Mechanism Description | miR375 overexpression could increase the cisplatin sensitivity of human gastric cancer cells by regulating ERBB2. | |||
Key Molecule: Delta-like protein 1 (DLL1) | [6] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Methotrexate | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | ATF2/ATF3/ATF4 signaling pathway | Inhibition | hsa04915 | |
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
MG63.2 cells | Bone | Homo sapiens (Human) | CVCL_R705 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
IC50 assay; Flow cytometric analysis | |||
Mechanism Description | miR34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene. The activity of the ATF2/ATF3/ATF4 pathway was reduced in the miR34a-5p mimic-transfected G-292 cells but increased in the miR34a-5p antagomiRtransfected SJSA-1 cells, hence the ATF2/ATF3/ATF4 pathway was validated to be involved in the OS chemoresistance mediated by miR34a-5p. | |||
Key Molecule: hsa-miR-34a-5p | [6] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Methotrexate | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | ATF2/ATF3/ATF4 signaling pathway | Inhibition | hsa04915 | |
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
MG63.2 cells | Bone | Homo sapiens (Human) | CVCL_R705 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
IC50 assay; Flow cytometric analysis | |||
Mechanism Description | miR34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene. The activity of the ATF2/ATF3/ATF4 pathway was reduced in the miR34a-5p mimic-transfected G-292 cells but increased in the miR34a-5p antagomiRtransfected SJSA-1 cells, hence the ATF2/ATF3/ATF4 pathway was validated to be involved in the OS chemoresistance mediated by miR34a-5p. | |||
Key Molecule: hsa-miR-34a-5p | [4] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Methotrexate | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Activation | hsa05200 | |
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
MEF2 signaling pathway | Regulation | hsa04013 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 | |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
MG63.2 cells | Bone | Homo sapiens (Human) | CVCL_R705 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | The down-regulation of CD117 mediated by miR-34a-5p might be one of the reasons for OS drug resistance. CD117 may also regulate other processes, including cell adhesion, differentiation and migration, which are significant for cancer development and treatment. | |||
Key Molecule: hsa-miR-146b-5p | [11] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Methotrexate | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell invasion | Activation | hsa05200 | ||
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
Wnt/Beta-catenin signaling pathway | Regulation | hsa04310 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
hFOB1.19 cells | Fetal bone | Homo sapiens (Human) | CVCL_3708 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | miR-146b-5p was highly expressed in human osteosarcoma tissues and an elevated expression of miR-146b-5p was observed in human osteosarcoma tissues after chemotherapy. Furthermore, it was shown that miR-146b-5p overexpression promoted migration and invasiveness. miR-146b-5p overexpression also increased resistance to chemotherapy. Moreover, knockdown of miR-146b-5p substantially inhibited migration and invasion of osteosarcoma cells as well as rendered them significantly more sensitive to chemotherapy. Results of western blot assay indicated that miR-146b-5p increased MMP-16 protein expression and showed a decrease of ZNRF3 protein. Whereas, IWR-1-endo, an inhibitor of Wnt/beta-catenin, suppressed the decrease in apoptosis of osteosarcoma cells caused by miR-146b-5p overexpression. These results indicated that miR-146b-5p promoted proliferation, migration and invasiveness. | |||
Key Molecule: hsa-mir-215 | [58] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Methotrexate | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell proliferation | Inhibition | hsa05200 | |
p53 signaling pathway | Activation | hsa04115 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
WST-1 assay | |||
Mechanism Description | miR-215, through the suppression of DTL expression, induces a decreased cell proliferation by causing G2-arrest, thereby leading to an increase in chemoresistance to MTX and TDX. | |||
Irregularity in Drug Uptake and Drug Efflux (IDUE) | ||||
Key Molecule: Multidrug resistance protein 1 (ABCB1) | [57] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Methotrexate | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell colony | Activation | hsa05200 | |
Cell senescence | Inhibition | hsa04218 | ||
Cell viability | Activation | hsa05200 | ||
LUCAT1/miR200c/ABCB1 pathway | Regulation | hsa05206 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HOS cells | Bone | Homo sapiens (Human) | CVCL_0312 | |
HFOB cells | Bone | Homo sapiens (Human) | CVCL_3708 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis; Luciferase reporter assay | |||
Experiment for Drug Resistance |
CCK8 assay; Transwell invasion assay | |||
Mechanism Description | LncRNA LUCAT1 and ABCB1 protein were both up-regulated in MG63/MTX and HOS/MTX cells when treated with methotrexate. ABCB1, acting as a vital protein of drug resistance, participated in the multiple drug resistance occurrence. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Mast/stem cell growth factor receptor Kit (KIT) | [4] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Methotrexate | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Activation | hsa05200 | |
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
MEF2 signaling pathway | Regulation | hsa04013 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 | |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
MG63.2 cells | Bone | Homo sapiens (Human) | CVCL_R705 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | The down-regulation of CD117 mediated by miR-34a-5p might be one of the reasons for OS drug resistance. CD117 may also regulate other processes, including cell adhesion, differentiation and migration, which are significant for cancer development and treatment. | |||
Key Molecule: E3 ubiquitin-protein ligase ZNRF3 (ZNRF3) | [11] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Methotrexate | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell invasion | Activation | hsa05200 | ||
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
Wnt/Beta-catenin signaling pathway | Regulation | hsa04310 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
hFOB1.19 cells | Fetal bone | Homo sapiens (Human) | CVCL_3708 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | miR-146b-5p was highly expressed in human osteosarcoma tissues and an elevated expression of miR-146b-5p was observed in human osteosarcoma tissues after chemotherapy. Furthermore, it was shown that miR-146b-5p overexpression promoted migration and invasiveness. miR-146b-5p overexpression also increased resistance to chemotherapy. Moreover, knockdown of miR-146b-5p substantially inhibited migration and invasion of osteosarcoma cells as well as rendered them significantly more sensitive to chemotherapy. Results of western blot assay indicated that miR-146b-5p increased MMP-16 protein expression and showed a decrease of ZNRF3 protein. Whereas, IWR-1-endo, an inhibitor of Wnt/beta-catenin, suppressed the decrease in apoptosis of osteosarcoma cells caused by miR-146b-5p overexpression. These results indicated that miR-146b-5p promoted proliferation, migration and invasiveness. | |||
Key Molecule: Dihydrofolate reductase (DHFR) | [58] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Methotrexate | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell proliferation | Inhibition | hsa05200 | |
p53 signaling pathway | Activation | hsa04115 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
Western blotting analysis; Immunofluorescence analysis | |||
Experiment for Drug Resistance |
WST-1 assay | |||
Mechanism Description | miR-215, through the suppression of DTL expression, induces a decreased cell proliferation by causing G2-arrest, thereby leading to an increase in chemoresistance to MTX and TDX. | |||
Key Molecule: Thymidylate synthase (TYMS) | [58] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Methotrexate | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell proliferation | Inhibition | hsa05200 | |
p53 signaling pathway | Activation | hsa04115 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
Western blotting analysis; Immunofluorescence analysis | |||
Experiment for Drug Resistance |
WST-1 assay | |||
Mechanism Description | miR-215, through the suppression of DTL expression, induces a decreased cell proliferation by causing G2-arrest, thereby leading to an increase in chemoresistance to MTX and TDX. |
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-mir-29a | [59] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Methotrexate | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | Overexpression of miR-29a suppressed MTX resistance and promoted cell apoptosis by downregulating MCL1 expression. | |||
Key Molecule: hsa-mir-29b | [59] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Methotrexate | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | Overexpression of miR-29b suppressed MTX resistance and promoted cell apoptosis by downregulating MCL1 expression. | |||
Key Molecule: hsa-mir-29c | [59] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Methotrexate | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | Overexpression of miR-29c suppressed MTX resistance and promoted cell apoptosis by downregulating MCL1 expression. | |||
Key Molecule: hsa-mir-382 | [31] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Methotrexate | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | Decreased miR-382 was associated with poor survival in OS patients. Overexpression of miR-382 inhibited cell growth and chemoresistance by targeting kLF12 and HIPk3, respectively. In contrast, inhibition of miR-382 or overexpression of target genes stimulated OS cell growth and chemoresistance both in vitro and in vivo. | |||
Key Molecule: hsa-mir-140 | [54] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Methotrexate | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell proliferation | Inhibition | hsa05200 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
WST-1 assay | |||
Mechanism Description | miR-140 is involved in the chemoresistance by reduced cell proliferation via G1 and G2 phase arrest mediated in part. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Collagen alpha-1(III) chain (COL3A1) | [59] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Methotrexate | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
Western blot analysis; RT-qPCR | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | Overexpression of miR-29a suppressed MTX resistance and promoted cell apoptosis by downregulating COL3A1 expression. | |||
Key Molecule: Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) | [59] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Methotrexate | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
Western blot analysis; RT-qPCR | |||
Experiment for Drug Resistance |
CCK8 assay; Flow cytometry assay | |||
Mechanism Description | Overexpression of miR-29a suppressed MTX resistance and promoted cell apoptosis by downregulating MCL1 expression. | |||
Key Molecule: Homeodomain-interacting protein kinase 3 (HIPK3) | [31] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Methotrexate | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | Decreased miR-382 was associated with poor survival in OS patients. Overexpression of miR-382 inhibited cell growth and chemoresistance by targeting kLF12 and HIPk3, respectively. In contrast, inhibition of miR-382 or overexpression of target genes stimulated OS cell growth and chemoresistance both in vitro and in vivo. | |||
Key Molecule: Krueppel-like factor 12 (KLF12) | [31] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Methotrexate | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | Decreased miR-382 was associated with poor survival in OS patients. Overexpression of miR-382 inhibited cell growth and chemoresistance by targeting kLF12 and HIPk3, respectively. In contrast, inhibition of miR-382 or overexpression of target genes stimulated OS cell growth and chemoresistance both in vitro and in vivo. | |||
Key Molecule: Histone deacetylase 4 (HDAC4) | [54] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Methotrexate | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell proliferation | Inhibition | hsa05200 | |
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
Western blotting analysis; Immunofluorescence analysis | |||
Experiment for Drug Resistance |
WST-1 assay | |||
Mechanism Description | miR-140 is involved in the chemoresistance by reduced cell proliferation via G1 and G2 phase arrest mediated in part. |
Oxycodone
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Drug Inactivation by Structure Modification (DISM) | ||||
Key Molecule: Cytochrome P450 family 3 subfamily A (CYP3A) | [60] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Oxycodone | |||
Experimental Note | Identified from the Human Clinical Data | |||
Mechanism Description | Oxycodone is a semisynthetic opioid receptor agonist, and is frequently used for pain control in patients with cancer. Most oxycodone is metabolized by N-demethylation to noroxycodone by CYP3A. Rifampin is a strong inducer of several drug-metabolizing enzymes, including CYP3A. Hence, rifampin-induced CYP3A activity may decrease the effect of oxycodone. |
Paclitaxel
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: Mitosis associated long intergenic non-coding RNA 1 (MALINC1) | [61] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Paclitaxel | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell proliferation | Activation | hsa05200 | |
In Vitro Model | H1299 cells | Lung | Homo sapiens (Human) | CVCL_0060 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
qPCR | |||
Experiment for Drug Resistance |
Flow cytometry assay | |||
Mechanism Description | Silencing of MA-linc1 in unsynchronized cells results in fewer cells in G1 and a concomitant increase in the number of cells in all other stages of the cell cycle, particularly in G2/M. Moreover, its silencing in M phase-arrested cells inhibits mitosis exit. The effect of MA-linc1 on cell cycle progression is mediated, at least in part, by repression of its neighboring gene, Puralpha, a cell cycle regulator whose expression induces cell cycle arrest. Importantly, high levels of MA-linc1 are correlated with decreased survival of breast and lung cancer patients and its silencing sensitizes cancer cells to the apoptotic effect of the M phase specific chemotherapeutic drug, Paclitaxel. This enhancement of Paclitaxel-induced apoptosis is also Puralpha-related. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Transcriptional activator protein Pur-alpha (PURA) | [61] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Paclitaxel | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell proliferation | Activation | hsa05200 | |
In Vitro Model | H1299 cells | Lung | Homo sapiens (Human) | CVCL_0060 |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
Flow cytometry assay | |||
Mechanism Description | Silencing of MA-linc1 in unsynchronized cells results in fewer cells in G1 and a concomitant increase in the number of cells in all other stages of the cell cycle, particularly in G2/M. Moreover, its silencing in M phase-arrested cells inhibits mitosis exit. The effect of MA-linc1 on cell cycle progression is mediated, at least in part, by repression of its neighboring gene, Puralpha, a cell cycle regulator whose expression induces cell cycle arrest. Importantly, high levels of MA-linc1 are correlated with decreased survival of breast and lung cancer patients and its silencing sensitizes cancer cells to the apoptotic effect of the M phase specific chemotherapeutic drug, Paclitaxel. This enhancement of Paclitaxel-induced apoptosis is also Puralpha-related. |
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-miR-422a | [22] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Paclitaxel | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Inhibition | hsa05200 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HFOB cells | Bone | Homo sapiens (Human) | CVCL_3708 | |
Experiment for Molecule Alteration |
qPCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometric analysis of apoptosis; Transwell assay | |||
Mechanism Description | Overexpression of miR422a inhibits cell proliferation and invasion, and enhances chemosensitivity by directly targeting TGFbeta2 in osteosarcoma cells. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Transforming growth factor beta-2 proprotein (TGFB2) | [22] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Paclitaxel | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Inhibition | hsa05200 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HFOB cells | Bone | Homo sapiens (Human) | CVCL_3708 | |
Experiment for Molecule Alteration |
Western blot analysis; Dual luciferase activity assay | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometric analysis of apoptosis; Transwell assay | |||
Mechanism Description | Overexpression of miR422a inhibits cell proliferation and invasion, and enhances chemosensitivity by directly targeting TGFbeta2 in osteosarcoma cells. |
Raltitrexed
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-mir-215 | [58] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Drug | Raltitrexed | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell proliferation | Inhibition | hsa05200 | |
p53 signaling pathway | Activation | hsa04115 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
WST-1 assay | |||
Mechanism Description | miR-215, through the suppression of DTL expression, induces a decreased cell proliferation by causing G2-arrest, thereby leading to an increase in chemoresistance to MTX and TDX. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Dihydrofolate reductase (DHFR) | [58] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Raltitrexed | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell proliferation | Inhibition | hsa05200 | |
p53 signaling pathway | Activation | hsa04115 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
Western blotting analysis; Immunofluorescence analysis | |||
Experiment for Drug Resistance |
WST-1 assay | |||
Mechanism Description | miR-215, through the suppression of DTL expression, induces a decreased cell proliferation by causing G2-arrest, thereby leading to an increase in chemoresistance to MTX and TDX. | |||
Key Molecule: Thymidylate synthase (TYMS) | [58] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Drug | Raltitrexed | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | Cell proliferation | Inhibition | hsa05200 | |
p53 signaling pathway | Activation | hsa04115 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
Western blotting analysis; Immunofluorescence analysis | |||
Experiment for Drug Resistance |
WST-1 assay | |||
Mechanism Description | miR-215, through the suppression of DTL expression, induces a decreased cell proliferation by causing G2-arrest, thereby leading to an increase in chemoresistance to MTX and TDX. |
Silibinin
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-mir-494 | [62] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Silibinin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
Experiment for Molecule Alteration |
qPCR | |||
Experiment for Drug Resistance |
TUNEL cell apoptosis assay; XTT cell proliferation assay; MTT cell proliferation assay; Colony formation assay | |||
Mechanism Description | MMP-9 was targeted and negatively regulated by hsa-miR494 which inhibited cell proliferation and induced cell apoptosis. Silybin inhibited OS cell viability by altering the protein levels of beta-catenin and RUNX2, thus upregulating the level of hsa-miR494. | |||
Regulation by the Disease Microenvironment (RTDM) | ||||
Key Molecule: Matrix metalloproteinase-9 (MMP9) | [62] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Silibinin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
Experiment for Molecule Alteration |
qPCR; Western blot analysis | |||
Experiment for Drug Resistance |
TUNEL cell apoptosis assay; XTT cell proliferation assay; MTT cell proliferation assay; Colony formation assay | |||
Mechanism Description | MMP-9 was targeted and negatively regulated by hsa-miR494 which inhibited cell proliferation and induced cell apoptosis. Silybin inhibited OS cell viability by altering the protein levels of beta-catenin and RUNX2, thus upregulating the level of hsa-miR494. |
Sirolimus
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-mir-410 | [20] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Sirolimus | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | HEK293T cells | Kidney | Homo sapiens (Human) | CVCL_0063 |
MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HFob 1.19 | Bone | Homo sapiens (Human) | CVCL_3708 | |
Experiment for Molecule Alteration |
RT-qPCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | microRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma, miR410 directly decreased ATG16L1 expression by targeting its 3'-untranslated region. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Autophagy-related protein 16-1 (ATG16L1) | [20] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Sirolimus | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | HEK293T cells | Kidney | Homo sapiens (Human) | CVCL_0063 |
MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HFob 1.19 | Bone | Homo sapiens (Human) | CVCL_3708 | |
Experiment for Molecule Alteration |
Luciferase reporter assay; Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | microRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma, miR410 directly decreased ATG16L1 expression by targeting its 3'-untranslated region. |
Epigallocatechin gallate
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-mir-126 | [63] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Epigallocatechin gallate | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
Experiment for Molecule Alteration |
Flow cytometry assay | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | Overexpression of miR-126 sensitizes osteosarcoma cells to apoptosis induced by epigallocatechin-3-gallate. |
Clinical Trial Drug(s)
1 drug(s) in total
Camptothecin
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-mir-124 | [50] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Camptothecin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
PI3K/AKT signaling pathway | Inhibition | hsa04151 | ||
In Vitro Model | MDA-MB-231 cells | Breast | Homo sapiens (Human) | CVCL_0062 |
T47D cells | Breast | Homo sapiens (Human) | CVCL_0553 | |
ZR75-1 cells | Breast | Homo sapiens (Human) | CVCL_0588 | |
HCC1937 cells | Breast | Homo sapiens (Human) | CVCL_0290 | |
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR-124 may be involved in DNA repair by directly targeting ATMIN and PARP1, suggesting that multiple DNA repair pathways are affected by miR-124 and therefore manipulation of miR-124 level/activity may improve the efficacy of chemotherapies that induce DNA damage. repression of ATMIN (+) the HR repair defect induced by miR-124, and restoration of ATMIN reversed the effect of miR-124 overexpression in breast cancer cells. Therefore, it is intriguing to further speculate which of the multiple roles of ATMIN is specifically affected in breast carcinogenesis. On the other hand, PARP1-mediated processes play a role in oncogenesis, cancer progression, and therapeutic resistance. | |||
Key Molecule: hsa-mir-103 | [33] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Camptothecin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
Survival assay/crystal violet staining assay | |||
Mechanism Description | miR-103 and miR-107 reduced homology-directed repair and sensitized cells to various DNA damaging agents, including cisplatin and a PARP inhibitor. Mechanistic analyses revealed that both miR-103 and miR-107 directly target and regulate RAD51 and RAD51D, which is critical for miR-103/107-mediated chemosensitization. | |||
Key Molecule: hsa-miR-107 | [33] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Camptothecin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
Survival assay/crystal violet staining assay | |||
Mechanism Description | miR-103 and miR-107 reduced homology-directed repair and sensitized cells to various DNA damaging agents, including cisplatin and a PARP inhibitor. Mechanistic analyses revealed that both miR-103 and miR-107 directly target and regulate RAD51 and RAD51D, which is critical for miR-103/107-mediated chemosensitization. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: ATM interactor (ATMIN) | [50] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Camptothecin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
PI3K/AKT signaling pathway | Inhibition | hsa04151 | ||
In Vitro Model | MDA-MB-231 cells | Breast | Homo sapiens (Human) | CVCL_0062 |
T47D cells | Breast | Homo sapiens (Human) | CVCL_0553 | |
ZR75-1 cells | Breast | Homo sapiens (Human) | CVCL_0588 | |
HCC1937 cells | Breast | Homo sapiens (Human) | CVCL_0290 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR-124 may be involved in DNA repair by directly targeting ATMIN and PARP1, suggesting that multiple DNA repair pathways are affected by miR-124 and therefore manipulation of miR-124 level/activity may improve the efficacy of chemotherapies that induce DNA damage. repression of ATMIN (+) the HR repair defect induced by miR-124, and restoration of ATMIN reversed the effect of miR-124 overexpression in breast cancer cells. Therefore, it is intriguing to further speculate which of the multiple roles of ATMIN is specifically affected in breast carcinogenesis. On the other hand, PARP1-mediated processes play a role in oncogenesis, cancer progression, and therapeutic resistance. | |||
Key Molecule: Poly[ADP-ribose] synthase 1 (PARP1) | [50] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Camptothecin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
PI3K/AKT signaling pathway | Inhibition | hsa04151 | ||
In Vitro Model | MDA-MB-231 cells | Breast | Homo sapiens (Human) | CVCL_0062 |
T47D cells | Breast | Homo sapiens (Human) | CVCL_0553 | |
ZR75-1 cells | Breast | Homo sapiens (Human) | CVCL_0588 | |
HCC1937 cells | Breast | Homo sapiens (Human) | CVCL_0290 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR-124 may be involved in DNA repair by directly targeting ATMIN and PARP1, suggesting that multiple DNA repair pathways are affected by miR-124 and therefore manipulation of miR-124 level/activity may improve the efficacy of chemotherapies that induce DNA damage. repression of ATMIN (+) the HR repair defect induced by miR-124, and restoration of ATMIN reversed the effect of miR-124 overexpression in breast cancer cells. Therefore, it is intriguing to further speculate which of the multiple roles of ATMIN is specifically affected in breast carcinogenesis. On the other hand, PARP1-mediated processes play a role in oncogenesis, cancer progression, and therapeutic resistance. | |||
Key Molecule: DNA repair protein RAD51 homolog 1 (RAD51) | [33] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Camptothecin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
Survival assay/crystal violet staining assay | |||
Mechanism Description | miR-103 and miR-107 reduced homology-directed repair and sensitized cells to various DNA damaging agents, including cisplatin and a PARP inhibitor. Mechanistic analyses revealed that both miR-103 and miR-107 directly target and regulate RAD51 and RAD51D, which is critical for miR-103/107-mediated chemosensitization. | |||
Key Molecule: DNA repair protein RAD51 homolog 4 (RAD51D) | [33] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Camptothecin | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
In Vitro Model | U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
Survival assay/crystal violet staining assay | |||
Mechanism Description | miR-103 and miR-107 reduced homology-directed repair and sensitized cells to various DNA damaging agents, including cisplatin and a PARP inhibitor. Mechanistic analyses revealed that both miR-103 and miR-107 directly target and regulate RAD51 and RAD51D, which is critical for miR-103/107-mediated chemosensitization. |
Preclinical Drug(s)
1 drug(s) in total
MRK-003
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Neurogenic locus notch homolog protein 1 (NOTCH1) | [64] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Missense mutation | p.A1552G (c.4655C>G) |
||
Sensitive Drug | MRK-003 | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | MDA-MB-157 cells | Breast | Homo sapiens (Human) | CVCL_0618 |
TNsBC cells | Breast | Homo sapiens (Human) | N.A. | |
T-ALL cells | Bone marrow | Homo sapiens (Human) | CVCL_1736 | |
HCC2218 cells | Breast | Homo sapiens (Human) | CVCL_1263 | |
HCC1187 cells | Breast | Homo sapiens (Human) | CVCL_1247 | |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
Cell Titer-Glo luminescent assay; Luciferase assay | |||
Key Molecule: Neurogenic locus notch homolog protein 1 (NOTCH1) | [64] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Missense mutation | p.A1552V (c.4655C>T) |
||
Sensitive Drug | MRK-003 | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | MDA-MB-157 cells | Breast | Homo sapiens (Human) | CVCL_0618 |
TNsBC cells | Breast | Homo sapiens (Human) | N.A. | |
T-ALL cells | Bone marrow | Homo sapiens (Human) | CVCL_1736 | |
HCC2218 cells | Breast | Homo sapiens (Human) | CVCL_1263 | |
HCC1187 cells | Breast | Homo sapiens (Human) | CVCL_1247 | |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
Cell Titer-Glo luminescent assay; Luciferase assay | |||
Key Molecule: Neurogenic locus notch homolog protein 1 (NOTCH1) | [64] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Missense mutation | p.E1567K (c.4699G>A) |
||
Sensitive Drug | MRK-003 | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | MDA-MB-157 cells | Breast | Homo sapiens (Human) | CVCL_0618 |
TNsBC cells | Breast | Homo sapiens (Human) | N.A. | |
T-ALL cells | Bone marrow | Homo sapiens (Human) | CVCL_1736 | |
HCC2218 cells | Breast | Homo sapiens (Human) | CVCL_1263 | |
HCC1187 cells | Breast | Homo sapiens (Human) | CVCL_1247 | |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
Cell Titer-Glo luminescent assay; Luciferase assay | |||
Key Molecule: Neurogenic locus notch homolog protein 1 (NOTCH1) | [64] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Missense mutation | p.A1570G (c.4709C>G) |
||
Sensitive Drug | MRK-003 | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | MDA-MB-157 cells | Breast | Homo sapiens (Human) | CVCL_0618 |
TNsBC cells | Breast | Homo sapiens (Human) | N.A. | |
T-ALL cells | Bone marrow | Homo sapiens (Human) | CVCL_1736 | |
HCC2218 cells | Breast | Homo sapiens (Human) | CVCL_1263 | |
HCC1187 cells | Breast | Homo sapiens (Human) | CVCL_1247 | |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
Cell Titer-Glo luminescent assay; Luciferase assay | |||
Key Molecule: Neurogenic locus notch homolog protein 1 (NOTCH1) | [64] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Missense mutation | p.V1575A (c.4724T>C) |
||
Sensitive Drug | MRK-003 | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | MDA-MB-157 cells | Breast | Homo sapiens (Human) | CVCL_0618 |
TNsBC cells | Breast | Homo sapiens (Human) | N.A. | |
T-ALL cells | Bone marrow | Homo sapiens (Human) | CVCL_1736 | |
HCC2218 cells | Breast | Homo sapiens (Human) | CVCL_1263 | |
HCC1187 cells | Breast | Homo sapiens (Human) | CVCL_1247 | |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
Cell Titer-Glo luminescent assay; Luciferase assay | |||
Key Molecule: Neurogenic locus notch homolog protein 1 (NOTCH1) | [64] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Missense mutation | p.V1599M (c.4795G>A) |
||
Sensitive Drug | MRK-003 | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | MDA-MB-157 cells | Breast | Homo sapiens (Human) | CVCL_0618 |
TNsBC cells | Breast | Homo sapiens (Human) | N.A. | |
T-ALL cells | Bone marrow | Homo sapiens (Human) | CVCL_1736 | |
HCC2218 cells | Breast | Homo sapiens (Human) | CVCL_1263 | |
HCC1187 cells | Breast | Homo sapiens (Human) | CVCL_1247 | |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
Cell Titer-Glo luminescent assay; Luciferase assay | |||
Key Molecule: Neurogenic locus notch homolog protein 1 (NOTCH1) | [64] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Missense mutation | p.V1676I (c.5026G>A) |
||
Sensitive Drug | MRK-003 | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | MDA-MB-157 cells | Breast | Homo sapiens (Human) | CVCL_0618 |
TNsBC cells | Breast | Homo sapiens (Human) | N.A. | |
T-ALL cells | Bone marrow | Homo sapiens (Human) | CVCL_1736 | |
HCC2218 cells | Breast | Homo sapiens (Human) | CVCL_1263 | |
HCC1187 cells | Breast | Homo sapiens (Human) | CVCL_1247 | |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
Cell Titer-Glo luminescent assay; Luciferase assay | |||
Key Molecule: Neurogenic locus notch homolog protein 1 (NOTCH1) | [64] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Missense mutation | p.I1680S (c.5039T>G) |
||
Sensitive Drug | MRK-003 | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | MDA-MB-157 cells | Breast | Homo sapiens (Human) | CVCL_0618 |
TNsBC cells | Breast | Homo sapiens (Human) | N.A. | |
T-ALL cells | Bone marrow | Homo sapiens (Human) | CVCL_1736 | |
HCC2218 cells | Breast | Homo sapiens (Human) | CVCL_1263 | |
HCC1187 cells | Breast | Homo sapiens (Human) | CVCL_1247 | |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
Cell Titer-Glo luminescent assay; Luciferase assay | |||
Key Molecule: Neurogenic locus notch homolog protein 1 (NOTCH1) | [64] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Missense mutation | p.R1683W (c.5047C>T) |
||
Sensitive Drug | MRK-003 | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | MDA-MB-157 cells | Breast | Homo sapiens (Human) | CVCL_0618 |
TNsBC cells | Breast | Homo sapiens (Human) | N.A. | |
T-ALL cells | Bone marrow | Homo sapiens (Human) | CVCL_1736 | |
HCC2218 cells | Breast | Homo sapiens (Human) | CVCL_1263 | |
HCC1187 cells | Breast | Homo sapiens (Human) | CVCL_1247 | |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
Cell Titer-Glo luminescent assay; Luciferase assay | |||
Key Molecule: Neurogenic locus notch homolog protein 1 (NOTCH1) | [64] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Missense mutation | p.A1707T (c.5119G>A) |
||
Sensitive Drug | MRK-003 | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | MDA-MB-157 cells | Breast | Homo sapiens (Human) | CVCL_0618 |
TNsBC cells | Breast | Homo sapiens (Human) | N.A. | |
T-ALL cells | Bone marrow | Homo sapiens (Human) | CVCL_1736 | |
HCC2218 cells | Breast | Homo sapiens (Human) | CVCL_1263 | |
HCC1187 cells | Breast | Homo sapiens (Human) | CVCL_1247 | |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
Cell Titer-Glo luminescent assay; Luciferase assay |
Investigative Drug(s)
1 drug(s) in total
Iridium
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-mir-124 | [50] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Drug | Iridium | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
PI3K/AKT signaling pathway | Inhibition | hsa04151 | ||
In Vitro Model | MDA-MB-231 cells | Breast | Homo sapiens (Human) | CVCL_0062 |
T47D cells | Breast | Homo sapiens (Human) | CVCL_0553 | |
ZR75-1 cells | Breast | Homo sapiens (Human) | CVCL_0588 | |
HCC1937 cells | Breast | Homo sapiens (Human) | CVCL_0290 | |
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR-124 may be involved in DNA repair by directly targeting ATMIN and PARP1, suggesting that multiple DNA repair pathways are affected by miR-124 and therefore manipulation of miR-124 level/activity may improve the efficacy of chemotherapies that induce DNA damage. repression of ATMIN (+) the HR repair defect induced by miR-124, and restoration of ATMIN reversed the effect of miR-124 overexpression in breast cancer cells. Therefore, it is intriguing to further speculate which of the multiple roles of ATMIN is specifically affected in breast carcinogenesis. On the other hand, PARP1-mediated processes play a role in oncogenesis, cancer progression, and therapeutic resistance. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: ATM interactor (ATMIN) | [50] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Iridium | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
PI3K/AKT signaling pathway | Inhibition | hsa04151 | ||
In Vitro Model | MDA-MB-231 cells | Breast | Homo sapiens (Human) | CVCL_0062 |
T47D cells | Breast | Homo sapiens (Human) | CVCL_0553 | |
ZR75-1 cells | Breast | Homo sapiens (Human) | CVCL_0588 | |
HCC1937 cells | Breast | Homo sapiens (Human) | CVCL_0290 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR-124 may be involved in DNA repair by directly targeting ATMIN and PARP1, suggesting that multiple DNA repair pathways are affected by miR-124 and therefore manipulation of miR-124 level/activity may improve the efficacy of chemotherapies that induce DNA damage. repression of ATMIN (+) the HR repair defect induced by miR-124, and restoration of ATMIN reversed the effect of miR-124 overexpression in breast cancer cells. Therefore, it is intriguing to further speculate which of the multiple roles of ATMIN is specifically affected in breast carcinogenesis. On the other hand, PARP1-mediated processes play a role in oncogenesis, cancer progression, and therapeutic resistance. | |||
Key Molecule: Poly[ADP-ribose] synthase 1 (PARP1) | [50] | |||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Drug | Iridium | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell invasion | Inhibition | hsa05200 | ||
Cell migration | Inhibition | hsa04670 | ||
Cell proliferation | Inhibition | hsa05200 | ||
PI3K/AKT signaling pathway | Inhibition | hsa04151 | ||
In Vitro Model | MDA-MB-231 cells | Breast | Homo sapiens (Human) | CVCL_0062 |
T47D cells | Breast | Homo sapiens (Human) | CVCL_0553 | |
ZR75-1 cells | Breast | Homo sapiens (Human) | CVCL_0588 | |
HCC1937 cells | Breast | Homo sapiens (Human) | CVCL_0290 | |
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | miR-124 may be involved in DNA repair by directly targeting ATMIN and PARP1, suggesting that multiple DNA repair pathways are affected by miR-124 and therefore manipulation of miR-124 level/activity may improve the efficacy of chemotherapies that induce DNA damage. repression of ATMIN (+) the HR repair defect induced by miR-124, and restoration of ATMIN reversed the effect of miR-124 overexpression in breast cancer cells. Therefore, it is intriguing to further speculate which of the multiple roles of ATMIN is specifically affected in breast carcinogenesis. On the other hand, PARP1-mediated processes play a role in oncogenesis, cancer progression, and therapeutic resistance. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.